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“You don´t need a weatherman to know which way the wind blows.” 
Bob Dylan 
  
 
ABSTRACT
Rectal cancer is diagnosed among 1200 men in Sweden every year. Current treatment for local and regional disease 
implies surgical resection of the rectum often in combination with preoperative radiotherapy (RT). This treatment 
results in a cancer-specific survival of approximately 90% after three years and a cumulative incidence of local 
recurrence of 5% after five years. The oncological benefits frequently come at the price of impaired bowel and 
sexual function with consequences for quality of life. To design a research project with the aim to investigate the 
effects of preoperative RT on testicular function and sexual health in men treated for rectal cancer a review of the 
available literature was performed. 
The findings of this review (Paper I) showed that the testicular dose (TD) was on average 3% to 17% of the pre-
scribed dose for RT. No reports on semen analysis in men treated for rectal cancer were identified. The androgen 
levels decreased in men treated with RT and the relative risk to have low serum testosterone (T < 8 nmol/l) was 2.7 
(95% CI 1.6 to 4.7; p<0.001) after four years. Low serum T was also related to post-treatment erectile dysfunction. 
Based on the results of Paper I, a cohort study with preoperative RT as exposure was initiated. One hundred and 
five men with rectal cancer stage I to III were included between April 2010 and May 2014. To increase the sample 
size of the unexposed group 63 men with prostate cancer planned to robot-assisted prostatectomy were included 
additionaly. All participants had a baseline and two follow-up visits 12 and 24 months after surgery to collect blood 
samples, patient-reported outcome measures and semen samples. Men receiving preoperative RT had an additional 
blood sample the week prior to surgery. 
The planned TD was calculated with the treatment planning system based on the planning computed tomography 
(CT) in 101 men (Paper II). The median planned TD for short course RT was 0.57 Gy (range 0.06 to 14.37 Gy) and 
0.81 Gy (range 0.36 to 10.80 Gy) for long course RT. In 32 men the delivered TD was assessed for each RT frac-
tion with repeated cone beam CT. The comparison between planned and delivered TD show that the planned TD is 
an accurate estimate of the delivered dose. The within-person variability of the delivered TD is related to the posi-
tion of the testes in men with moderate to high TD. 
The androgen levels at baseline of the entire cohort were similar and independent of the type of preoperative RT or 
the type of cancer (Paper III). Preoperative RT resulted in a significant decrease of T and increase of luteinising 
hormone (LH) and LH-T ratio. The risk of low serum T (T < 8 nmol/l) increased from 14.6% at baseline to 35.5% 
at the time of surgery in men treated with RT corresponding to a relative risk of 2.41 (95% CI 1.57 to 3.71, 
p<0.001). These findings confirm that preoperative RT leads to primary testicular failure. The preliminary analy-
sis indicates a dose-response relationship between the TD and the negative impact on testicular function. 
The biochemical signs of testicular failure persisted in 40 men analysed 12 months after surgery (Paper IV). The 
cross-sectional area of the psoas and erector spinae muscle, assessed on routinely acquired planning and follow-up 
CT, was related to the level of bioavailable T. The area of subcutaneous tissue was not related to androgen levels. 
The decrease in these muscle groups is an androgen-dependent sign and identified men with testicular failure that 
had T levels in the grey zone of hypogonadism one year after surgery. 
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BACKGROUND
Rectal cancer 
The rectum, the final segment of the gastrointestinal tract, extends 15 cm from the anal verge in oral direction and 
is a part of the large intestine with specific functions. The faeces accumulate in the rectum to enable controlled 
discharge in cooperation with the anal canal. Malignant transformation of the mucosa in the large intestine results 
in an adenocarcinoma named colorectal cancer (CRC). Colorectal cancer accounts for 10% of the total cancer 
burden 1. It is the second most common cancer in women and the third most common cancer in men 
worldwide. The age-standardized incidence rates of CRC vary ten-fold across the world with the highest 
estimated rates in Australia/ New Zealand (32.2 and 44.8 per 100 000 in women and men respectively) and the 
lowest rates in Western Africa (3.8 and 4.5 per 100 000). The geographical variability in mortality rates is six-fold 
in men and four-fold in women, indicating poorer survival in less developed regions of the world. 
Sweden is one of the countries with very high incidence rate of CRC 2. One third of CRC occur in the rectum result-
ing in 1200 men and 800 women with diagnosis of rectal cancer in Sweden every year 3. The age-standardized 
incidence has been stable between 1980 and 2012 and mortality is slightly decreasing. 
Determinants of colorectal cancer 
Age and family history 
The lifetime risk of CRC is 5.9% in men and 5.5% in women 4. Age is the most prominent risk factor as 90% of 
new cases occur after age 50 5. About 25% of affected patients have family history of CRC. The relative risk (RR) 
of CRC is 2.24 (95% CI 2.06 to 2.43) for one first-degree relative with CRC and 3.97 (95% CI 2.60 to 6.06) for at 
least two first-degree relatives 6. Specific inherited syndromes account for 5% of CRC. The lifetime risk of CRC in 
Lynch syndrome families is 43% in women and 66% in men with a median age at diagnosis of 47 and 42 years 
respectively 7. Familial adenomatous polyposis is the second most common cause of hereditary CRC. Affected 
individuals develop hundreds to thousands of adenomas in the colon and rectum early in life. The lifetime risk of 
CRC approaches 100% by age 40 8. 
Personal history 
Personal history of CRC increases the risk of a second, metachronous CRC, which is the reason for 
postoperative colonoscopic surveillance. The postoperative adenoma-free survival is related to sex, age and 
number of synchronous lesions at the time of surgery 9. Removal of high-risk adenomas in the personal history 
results in a standardized mortality ratio (SMR) of 1.16 (95% CI 1.02 to 1.31) for CRC after a median follow-up of 
7.7 years 10. In contrast the CRC mortality is lower after removal of low risk adenomas, SMR 0.75 (95% CI 0.63 
to 0.88).
The risk of CRC in inflammatory bowel disease is debated but severe long-standing colitis and primary 
sclerosing cholangitis seem to be of importance. The meta-analysis of eight population-based cohort studies, 
which includes five studies from Scandinavian countries, reports a relative risk of CRC for ulcerative colitis of 
2.4 (95% CI 2.1 to 2.7) 11. Young age at diagnosis, male gender and extensive disease are risk factors. The absolute 
risk of CRC in this pooled study population with ulcerative colitis is 1.6% including the sporadic cases of CRC 
during a median follow up of 7 to 24 years. The cumulative probability of CRC is considerably lower than 
reported earlier with a cancer risk of 2% after 10 years, 8% after 20 years and 18% after 30 years 12. The 
standardized incidence ratio for CRC risk in Crohn´s disease seems even smaller, 1.7 (95% CI 1.01 to 2.5) 13. 
Diabetes mellitus increases the risk of CRC and mortality, HR 1.26 (95% CI 1.12 to 1.34) and HR 1.30 (95% CI 
1.15 to 1.47) respectively, in study populations with predominantly type 2 diabetes 14. 
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Overweight and obesity are suspected to account for 20% of all cancers worldwide 15. The relative risk of CRC in 
obese women is inconsistent and two of three meta-analysis report an increase, RR 1.15 (95% CI 1.06 to 1.24) 16. 
The association is stronger in men with RR ranging from 1.37 (95% CI 1.21 to 1.56) to 1.95 (95% CI 1.59 to 2.39). 
Behavioural factors (diet, tobacco, alcohol and physical activity) 
Mediterranean diet, composed of vegetables, fruits, cereals, olive oil and moderate amount of red wine, has a 
protective effect regarding CRC, RR 0.86 (95% CI 0.80 to 0.93) 17. The use of diet supplements containing multi-
vitamins, RR 0.92 (95% CI 0.87 to 0.97), or calcium, RR 0.86 (95% CI 0.94 to 0.99), seem to be protective where-
as the associations are inconsistent for supplements with vitamin A, C, D or E, garlic and folic acid 18. Daily intake 
of 100g red meat or 50g processed meat results in RR 1.27 (95% CI 1.16 to 1.40) and 1.29 (95% CI 1.10 to 1.53) 
respectively 19. The effect of tobacco use on CRC risk is inconsistent and smokeless tobacco, Scandinavian moist 
snuff (snus), is not associated with an elevated risk for CRC in men 20. Smoking increases the risk for cancer in 
the colon, HR 1.08 (95% CI 0.99 to 1.19), and in the rectum, HR 1.16 (95% CI 1.04 to 1.30). A meta-analysis 
of prospective studies yields similar findings with RR 1.15 (95% CI 1.00 to 1.32) in current smokers and 1.20 
(95% CI 1.04 to 1.38) in former smokers 21. This publication also reports a stronger association for smoking with 
rectal than colonic cancer and there is evidence for a dose-response relationship between smoking and CRC 
incidence. The relation of alcohol consumption and CRC mortality seems to be dose-dependent as only the intake 
of more than 50 g of ethanol per day is associated with an elevated risk for death due to CRC, RR 1.21 (95% CI 
1.01 to 1.46) 22. The results regarding the protective effect of physical activity on CRC risk are inconsistent. The 
latest systematic reviews report a reduced risk to develop colon cancer but no effect on the risk for rectal cancer 23 
24. The findings of a case-control study from Western Australia suggest that vigorous physical activity is required
to reduce the risk for CRC and that the effect is pronounced for the distal colon 25. Vigorous physical 
activity reduces the risk for rectal cancer in men but not in women. Physical activity has also an impact on 
survival 26. Any amount of physical activity before the diagnosis of CRC reduces cancer-specific mortality, RR 
0.75 (95% CI 0.65 to 0.87). Physical activity after the diagnosis of CRC has a similar effect on cancer-specific 
survival, RR 0.74 (95% 0.58 to 0.95). The insulin-like growth factor axis is supposed to play a central role in 
the inverse relationship between physical activity and CRC survival 27.
The joint effect of these behavioural factors is of interest as these factors are recognized as healthy lifestyle and 
can be present simultaneously. The HR for CRC is 0.87 (95% CI 0.76 to 0.98) for the presence of two healthy 
lifestyle factors and decreases to HR 0.63 (95% CI 0.54 to 0.75) if five healthy lifestyle factors (BMI<25kg/m2, 
high physical activity, non-smoker, adequate alcohol consumption and healthy diet) are present 28. The findings of 
this publication suggest that 16% of new CRC cases are attributable to not fulfilling the five healthy lifestyle 
factors.  
Aspirin (acetylsalicylic acid) 
Aspirin and other non-steroidal anti-inflammatory drugs are substances that have repeatedly been studied regarding 
their preventive effect on CRC development. Recent findings suggest a heterogeneous effect of aspirin related to 
the hydroxyprostaglandin dehydrogenase 15 (15-PGDH) expression in the colonic mucosa 29. The 15-PGDH en-
zyme is a metabolic antagonist of the prostaglandin-endoperoxide synthase 2 (PTGS2), also known as cyclooxy-
genase-2 (COX-2), and is down regulated in CRC. Regular aspirin use is not associated with the risk of CRC in 
individuals with low expression of 15-PGDH mRNA, HR 0.90 (95% CI 0.63 to 1.27). High colonic expression of 
15-PGDH and aspirin use is related to marked reduction of CRC risk, HR 0.49 (95% CI 0.34 to 0.71). Aspirin has 
also promising effects after treatment of CRC. The adjuvant use of aspirin does not enhance cancer-specific or 
overall survival in individuals with wild-type CRC for the gene encoding phosphatidylinositol-4,5-bisphosphonate 
3-kinase catalytic subunit alpha polypeptide (PIK3CA), HR 0.96 (95% CI 0.69 to 1.32) and HR 0.94 (95% CI 0.75 
to 1.17) respectively 30. Up-regulation of phosphatidylinositol 3-kinase (PI3K) increases PTGS2 activity and syn-
thesis of prostaglandin E2, which inhibits apoptosis of CRC cells. The regular use of aspirin results in improved 
cancer-specific and overall survival among patients with mutated-PIK3CA cancers, HR 0.18 (95% CI 0.06 to 0.61) 
and HR 0.54 (95% CI 0.31 to 0.94). This astonishing effect of aspirin on CRC survival is confirmed in participants 
of a randomized trial investigating the effect of rofecoxib, a selective COX-2 inhibitor, on CRC survival 31. The 
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recurrence-free survival, HR 0.11 (95% CI 0.001 to 0.832), and the overall survival, HR 0.29 (95% CI 0.04 to 
2.33), improve in patients with mutated-PIK3CA cancers that had a long-term low dose aspirin therapy (< 100 mg 
per day) at the time of randomization or commenced with low dose aspirin during follow-up. Rofecoxib has no 
benefit in mutated-PIK3CA cancers. In contrast to the two previous studies the analysis of PTGS2 expression and 
PIK3CA mutation seems not to identify individuals with benefit of aspirin in a Dutch cohort study assessing the 
effect of aspirin use on CRC survival 32. In this study patients with colon cancer expressing the HLA class I antigen 
have a significantly longer survival, RR 0.53 (95% 0.38 to 0.74), if they use aspirin after CRC diagnosis. The loss 
of HLA class I antigen expression in the tumours is associated with no survival benefit from aspirin use, RR 1.03 
(95% CI 0.66 to 1.61). The molecular mechanisms resulting in an anticancer effect of aspirin remain incompletely 
understood. The discussed studies explain the high interest that this old and commonly used substance actually has 
regarding chemoprevention and adjuvant therapy of CRC. 
Milestones in treatment of rectal cancer 
The ancient Egyptians collected knowledge of anorectal diseases. Several rectal procedures and medications are 
documented on the Ebers and the Chester Beatty Medical Papyrus 33. Herodotus, a fifth century Greek historian, 
concluded after his studies at the Library of Alexandria that rectal cancer was a disease without cure 34. It took more 
than a millennium until Giovanni Morgagni proposed to resect the rectum for treatment of rectal cancer during the 
18th century. Several French surgeons contributed to advances in rectal surgery 35. The first diverting procedure is 
assigned to Henry Pillore that performed an elective cecostomy to release an obstructing cancer of the rectum in 
1776. Jean Zulema Amussat, experienced from battlefield operations during the Napoleonic wars, established the 
formation of a colostomy as treatment for rectal cancer. The excision of a distal rectal tumour by Jacques Lis-Franc 
1826, using a perineal approach, is the first documented resection for rectal cancer. Success at the time was the 
ability of the patient to leave the hospital after survival of postoperative haemorrhage. These early reports of rectal 
cancer treatment sent a shiver down the reader´s spine, as general anaesthesia and bleeding control other than 
compression were unavailable. The introduction of anaesthesia, asepsis and bowel anastomosis techniques facilitat-
ed the progress in surgery for rectal cancer. The Swiss surgeon Theodor Kocher evolved 1874 a technique with 
closure of the anus to avoid spillage, partial sacrectomy to enhance exposure for the resection of the rectum and the 
formation of an artificial sacral anus 36. 
Abdominoperineal excision 
William Ernest Miles performed 57 perineal resections between 1899 to 1906 and 95 per cent of the patients had 
local recurrences within three years 37. From the findings of the post-mortem examinations Miles concluded that the 
zone of upward spread of cancer from the rectum has to be removed in analogy to 
clearance of the axilla in cases of breast cancer. He proposed an en bloc resection of 
the pelvic colon, the pelvic mesocolon and iliac lymph nodes in combination with a 
wide perineal excision to prevent the cylindrical spread of cancer cells. The abdom-
inoperineal excision (APE) was performed in 75 to 90 min with the patient in right 
lateral semi-prone position during the perineal excision. The postoperative mortality 
was 41.6% after 12 operations. The frequency of local recurrence decreased from 
95% to 29.5% in APEs performed by Miles 38. 
Figure 1. Sir William Ernest Miles 
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The need of a permanent stoma and the consequences of radical APE regarding functional outcomes encouraged 
sphincter-saving procedures. Claude Dixon, a surgeon at the Mayo Clinic, reported a hospital mortality of 5.9% and a 
five-year survival of 67.7% in 426 anterior resections performed during 1930 to 1947 for cancer in the upper or mid 
rectum. The development of stapling devices, introduced to clinical practice of Humer Hultl in Hungary 1908, facilitat-
ed the consecutive advancement in surgical treatment of rectal cancer 39. A scientific research program, initiated in the 
Soviet Union during World War II, resulted in stapling guns used for intestinal and vascular anastomosis. This tech-
nique fascinated Mark Ravitch, a paediatric surgeon from the United States, during his visit to the Soviet Union in 
1958. The following American modifications of the devices promoted the widespread use of mechanical suturing. 
Total mesorectal excision 
The principles of surgical oncology, defined by an en bloc resection of the affected bowel segment with the sur-
rounding lymphatic tissue as described for example by W. E. Miles, were not applied consistently. The blunt dis-
section in the pelvis, accompanied by a characteristic sucking noise, frequently left “blocks of fatty lymphovascular 
tissue” along the pelvic sidewall. Serious intraoperative bleeding and cumbersome local recurrence were common to 
occur 40. In 1982, Professor Bill Heald from the Basingstoke District Hospital, UK, described total mesorectal exci-
sion (TME), the state-of-the-art technique for surgical treatment of rectal cancer today  41. Sharp scissor dissection 
under direct vision along embryological planes resulted in adequate cancer clearance and reduced adverse events 
due to autonomic nerve injury. None of the 50 patients with complete cancer clearance developed local recurrence 
after a minimum of two years of follow-up. In 1986 the five-year results of 115 patients with curative anterior 
resection in TME technique showed an overall survival of 87.5% and a cancer-free survival of 81.7%. The 
estimated probability of local recurrence was 3.7% without the use of radiation or chemotherapy. Professor Phil 
Quirke, pathologist in Leeds, reported the same year that 14 of 52 rectal cancer specimens had tumour spread to the 
lateral resection margin and 12 of these patients developped local pelvic recurrence 42. Tumour involvement of the
circumferential margin, defined as cancer cells within 1 
mm from the lateral surface of the specimen, turned out 
to be an important predictor of local recurrence and sur-
vival, HR 3.68 (95% CI 2.32 to 5.83) and 2.16 (95% CI 
1.53 to 3.05) respectively 43. The contributions of Heald 
and Quirke enabled to set standards for anterior resection 
and the pathologic assessment of the specimen with a 
positive impact on patient outcome. The work-shops in 
Stockholm, initiated 1994, resulted in significant 
improvements regarding frequency of permanent stoma 
formation, local recurrence and cancer-specific mortality 
in a study population with a frequency of preoperative 
radiotherapy around 50% 44. 
Figure 2. Plane of excision in TME 41 (reprint with per-
mission) 
Radiotherapy 
While Heald described the TME technique, several randomized trials explored the effect of radiotherapy (RT) on 
local recurrence to define the optimal biologically effective dose (BED), fractionation and time-point (pre- or post-
operative) for RT in rectal cancer. Many of these studies were conducted in Sweden. 
The Uppsala Trial compared preoperative short course RT (5 x 5.1 Gy) versus postoperative long course RT (30 x 2 
Gy). The local recurrence rate was lower for preoperative short course RT (13% vs. 22%, p=0.02) after a minimum 
follow-up of five years with similar overall survival 45. 
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In the Stockholm I Trial participants were assigned to surgery alone or preoperative short course RT (5 x 5 Gy) 
followed by surgery. The risk of pelvic recurrence was lower in patients treated with RT (14% vs. 28%, p<0.01) but 
no effect on overall survival was registered 46. The increased postoperative mortality, observed in patients treated 
with RT (8% vs. 2%, p<0.01), was mainly due to cardiovascular events in patients over age 75. 
The Stockholm II Trial had a similar study design but with a four-field box RT technique to decrease the target vol-
ume and was restricted to patients under the age of 80. The incidence of local recurrence was similar (12% vs. 25%, 
p<0.001) in favour of RT and the 30-day postoperative mortality decreased (2% vs. 1%, ns) 47. The intention-to-
treat analysis showed no effect on overall survival. Patients with curative surgery, defined as R0 resection in stage I 
to III disease and a specimen with tumour free margins, had a benefit in overall and cancer-specific survival, HR 
0.77 (95% CI 0.61 to 0.98, p=0.03) and HR 0.60 (95% CI 0.45 to 0.80, p<0.001) respectively. 
The Swedish Rectal Cancer Trial had the same protocol as the Stockholm II Trial and included participants from 70 
Swedish hospitals. In addition to a comparable effect on local recurrence (11% vs. 27%, p<0.001) a survival benefit 
in the intention-to-treat analysis was reported 48. The difference in overall survival, HR 0.79 (95% CI 0.66 to 0.92), 
and cancer-specific survival, HR 0.69 (95% CI 0.55 to 0.83), was regarded reliable after comparison with the 
population-based Swedish Cancer Registry 49. 
These benefits of RT regarding local recurrence and survival were observed in randomized trials without 
standardized surgical technique for anterior resection and APE. The Dutch TME Trial closed this gap by rando-
mizing patients with stage I to III disease between TME surgery alone and preoperative short course RT (5 x 5 Gy) 
followed by TME surgery. A total of 1748 participants were evaluated after exclusion of 57 patients with 
macroscopically incomplete (R2) resection. The proportion of specimens with positive circumferential margin was 
16% in both groups. After 10 years of follow up the cumulative incidence of local recurrence was 5% vs. 11% 
(p<0.0001) in favour of preoperative RT 50. No difference in overall or cancer-specific survival was observed and 
25% vs. 28% (p=0.21) developed distant metastasis. The effect of preoperative RT was most convincing in stage III 
disease and increased cancer-specific survival in patients with negative circumferential margin. 
The MRC CR07/ NCIC-CTG C016 Trial recommended TME technique and randomly assigned patients with resec-
table tumours to preoperative short course RT (5 x 5 Gy) or selective postoperative chemoradiotherapy (25 x 1.8 
Gy) in case of circumferential margin involvement 51. Preoperative short course RT resulted in enhanced local con-
trol, HR 0.39 (95% CI 0.27 to 0.58, p<0.0001), and cancer-specific survival, HR 0.76 (95% CI 0.62 to 0.94, 
p=0.013). The proportion of specimens classified with good (mesorectal) plane of surgery was 52% and 11% had 
an involved circumferential margin 52. The plane of surgery was an important prognostic factor for local recurrence 
and the combination of preoperative RT and correct plane of surgery almost abolished the risk of local recurrence. 
Other European studies assessed the effect of long course RT (prescribed dose between 45 to 50.4 Gy) and the addi-
tion of chemotherapy. The European Organisation for Research and Treatment of Cancer (EORTC) initiated the 
EORTC 22921 Trial in 1993, which included 1011 patients (T3/ T4 M0 tumours) in four arms to evaluate the ef-
fects of long course RT (25 x 1.8 Gy) in combination with fluorouracil-based chemotherapy 53. Surgical resection 
was performed in 966 participants with 787 R0 resections. The addition of neoadjuvant chemotherapy enhanced 
preoperative downsizing and downstaging 54. The surgical technique was not standardized as TME was recom-
mended just after 1999 and the type of surgery was unknown in about 50% of resections. After 10 years of follow-
up the proportion of local recurrence was significantly increased for patients treated only with RT (22%, p=0.0017). 
Adjuvant chemotherapy had no effect on disease-free or overall survival but less than half of the patients assigned 
to postoperative chemotherapy could be treated with the intended dose 55. The German trial CAO/ARO/AIO-94, 
comparing pre- and postoperative chemotherapy in combination with long course RT, reported similar findings and 
difficulties to deliver postoperative chemotherapy 56. Preoperative chemotherapy had a benefit on local control but 
no differences regarding survival or cumulative incidence of distant metastasis. The French trial FFCD 9203 also 
found an advantage in local control if preoperative chemotherapy was added to long course RT 57. In T4 or 
recurrent rectal cancer preoperative chemoradiotherapy improved local control and cancer-specific survival 
compared to long course RT (25 x 2 Gy) 58. Two similar trials compared preoperative short course RT (5 x 5 Gy) to 
preoperative chemoradiotherapy (28 x 1.8 Gy) and found no difference in survival, local control or toxicity 59 60. 
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In summary neoadjuvant RT in rectal cancer reduces the RR of local recurrence by 50% to 70% and may enhance 
survival 61. Radiotherapy for rectal cancer is best given before surgery. The effect on local recurrence and survival is 
probably not different in short or long course RT but at the price of increased costs and resource requirements for 
long course RT due to the number of RT fractions and the need of concomitant chemotherapy. Experiences from the 
Stockholm III Trial, that completed inclusion in 2013, indicate a similar effect on downsizing for short course RT 
and delayed surgery 62. The addition of chemotherapy to preoperative RT enhances local control and a significant 
survival gain was only observed in locally advanced cancers. The results of randomized trials do not support the 
idea that preoperative (chemo)radiotherapy increases the proportion of sphincter-saving anterior resections 63. 
Revised abdominoperineal excision 
The Dutch TME Trial with surgeons trained in TME detected an alarming difference in survival between APE and 
anterior resection 64. Increased proportion of positive circumferential margins, intraoperative perforations and 
inadequate planes of resection were identified as potential factors for the inferior outcome of APE. The pooled 
analysis of five randomised clinical trials on rectal cancer resulted in an increased risk of margin involvement, OR 
2.52 (95% CI 1.69 to 3.76, p<0.001), local recurrence, HR 1.36 (95% CI 1.07 to 1.72, p=0.011), and decreased 
cancer-specific survival, HR 1.31 (95% CI 1.11 to 1.56, p=0.002), for APE 65. The TME technique defines the 
plane of surgery in anterior resection and is the standard to be reproduced and teached. This is not the case for 
conventional APE, often the only choice in low rectal cancer growing into the anal sphincter or levator ani muscle. 
Professor Torbjörn Holm from the Karolinska University Hospital, Stockholm, refined the technique of APE by 
combining the TME principles, precise dissection along defined anatomical planes free of tumour growth, with the 
technique for the perineal part of the operation described by Miles. The extended APE begins as TME in the 
abdomen yet avoids dissecting the mesorectum off the levator muscles. The patient is then turned into prone 
position to complete the perineal excision by resecting anus, lower rectum and levator muscles en bloc 66. 
The resulting specimen has in contrast to the conventional APE no waist at the proximal end of the anal canal. The
technique described by Holm is also called extralevator APE (ELAPE or eAPE) due to the plane of surgery during 
the perineal excision or cylindrical APE due to the shape of the resulting specimen. The amount of tissue removed 
outside the smooth muscle layer increases with extralevator APE and the proportion of specimens with involved 
circumferential margin or in-traoperative perforation decreases 67. In 193 patients treated at Karolinska University 
Hospital for low T3 or T4 rectal cancer on preoperative magnetic resonance imaging (MR) since 2000 the 
proportion of circumferential margin involvement and intraoperative perforation was 10% each 68. The rate of local 
recurrence was 6% and 24% died from rectal cancer after a median follow-up of three years not considering 3% 30-
day mortality. The core issue of extralevator APE, elimination of waisted APE specimens, has been applied earlier 
at the Mayo Clinic with excellent oncologic outcome under the label standard APE 69. In analogy to the extralevator 
APE two additional variants of the perineal part can be defined 70. The intersphincteric APE combines TME with 
resection of the anal canal preserving the external anal sphincter and the pelvic floor in patients not suitable for 
bowel reconstruction without tumour growth into the anal sphincter or levator ani muscle. The ischioanal APE 
includes a wide excision of the perianal skin and the ischioanal adipose tissue by lateral dissection toward the 
ischial tuberosity. The plane of surgery follows the fascia of the internal obturator muscle up to the lateral insertion 
of the levator ani muscle and is applied in patients with tumour perforation through the pelvic floor or anal 
abscesses/ fistulae with tumour growth. In the light of modern rectal cancer treatment a randomized trial to compare 
extralevator versus conventional APE, a surgical technique without definition of anatomical planes, seems not 
feasible and ethically controversial. The meta-analysis of comparative studies until May 2013 showed marked 
advantages of extralevator APE regarding the frequency of circumferential margin involvement, intraoperative 
perforation and local recurrence 71. The results of population-based cohort studies failed to show an advantage of 
extralevator APE, however, the validity of these results is questionable 72 73. The Spanish study used a propensity 
score to perform a one-to-one match of 457 individuals in each group from originally 1490 conventional APEs and 
480 extralevator APEs. This study design raises concerns, as several matching factors (i.e. R0, circumferential 
margin and quality of mesorectal excision) are intermediate factors between exposure (type of APE) and outcome 
(local recurrence). This implies high risk of selection bias due to overmatching. In the Swedish study the exposure 
status, conventional or extralevator APE, could not be defined in 44.5% of the study population. After exclusion of  
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the “not stated” group the two groups available for analysis, conventional versus extralevator APE, differ regarding 
tumour height and frequency of preoperative chemoradiotherapy usually applied in more advanced tumours. This 
selection results in comparison between low and advanced tumours in the extralevator APE group versus higher and 
less advanced tumours in the conventional APE group. 
Extensive surgery for locally advanced or recurrent rectal cancer 
Despite the introduction of screening programs and multimodal treatment of rectal cancer some patients still present 
with primary rectal cancer growing into other pelvic structures or pelvic recurrence of rectal cancer. Uncontrolled 
pelvic tumour growth has a disastrous impact on patient´s life and median survival for locally recurrent rectal can-
cer treated with supportive care is limited to few months 74. Extensive surgery including multivisceral resection 
(pelvic exenteration), sacral resection and hemipelvectomy are procedures to enable tumour clearance as R0 resec-
tion is a strong predictor for the oncologic outcome in these patients 75 76. The status of the resection margin is more 
important for long-term survival than the fact that surgery is performed for primary advanced or recurrent rectal 
cancer 77. The five-year overall survival after treatment with curative intent of recurrent rectal cancer has improved 
over time and can reach 50% in selected series 78 79. The Beyond TME Collaborative has published a consensus 
statement for staging and treatment of these patients with complex presentation of rectal cancer diseases 80. This 
type of demanding pelvic surgery seems to require a minimum of 14 cases for a surgical team headed by an expert 
colorectal surgeon to reduce perioperative complications 81. 
Current multimodal therapy of rectal cancer stage I to III 
Curative treatment for primary rectal cancer should aim for less than 5% risk of residual disease in the pelvis and 
the expected gains of additional treatments such as RT, chemotherapy and more extensive surgery should motivate 
the increased morbidity 82. “Name it, stage it, treat it” is an established sequence for cancer care. Medical history, 
physical examination and venous blood sample (blood count, liver and renal function, carcinoembryonic antigen) 
are completed with digital rectal examination and rectoscopy with biopsy to confirm diagnosis of primary rectal 
cancer. To enable individualized risk assessment dedicated MR of the pelvis and computed tomography (CT) of the 
chest and abdomen are required to stage the disease. Synchronic lesions of the colon are excluded by complete 
colonoscopy and endoscopic rectal ultrasound may be useful to assess the depth of invasion in the earliest tumours. 
This workup should provide morphological verification and TNM classification of the rectal lesion. The distance 
between the lower end of the tumour and the anal verge, extramural vascular invasion, tumour growth in relation to 
the mesorectal fascia and invasion of other pelvic structures/ organs are additional criteria to discuss the treatment 
strategy at the multidisciplinary team conference (MDT). Risk stratification on four levels is recommended to 
choose the treatment modalities in rectal cancer stage I to III and patient´s preferences/ conditions are considered 
for individualized therapy. Complete surgical resection is the most important treatment modality and should be per-
formed according to standardized techniques. Radiotherapy and chemotherapy are preferably given before surgery, 
as the preoperative treatment is more effective and less toxic than the postoperative treatment. 
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Table 1. Tailored treatment for primary rectal cancer stage I to III (adapted 82)
Risk group Height Clinical stage Treatment 
Very early any T1 sm1(-2?) N- 
Local excision 
Complete with resection (or CRT) if sm ≥ 2, high 
grade or vascular invasion  
Early (“good”) 
upper T3a/b N±, mrf-, EMVI- Standard resection 
Complete with Cx or CRT if CRM+ or pN2 middle T3a/b N-, mrf-, EMVI- 
low T1-2 N-, mrf-, EMVI- 
Intermediate 
(“bad”) 
upper T3mrf-, N+, EMVI+ 
limited T4a N- 
Preop RT/ CRT and standard resection middle T3mrf-, N+, EMVI+ 
limited T4a N- 
low T2 mrf- 
Advanced 
(“ugly”) any 
T3 mrf+, T4, lateral nodes+ 
Preop CRT and extended resection 
alt. preop RT and delayed extended resection if Cx 
not tolerated 
T=tumour stage, N=nodal stage, sm=submucosal invasion level, mrf=mesorectal fascia, EMVI=extramural vascular invasion,
CRM=circumferential resection margin, RT=radiotherapy, CRT=chemoradiotherapy, Cx=chemotherapy 
The postoperative MDT conference is the opportunity to perform a product analysis based on a standardized speci-
men evaluation by the pathologist. The pathologist personally should examine the specimen before and after fixa-
tion to ensure high interrater reliability 83. Chemotherapy is the weakest modality for treatment of rectal cancer. In 
analogy to treatment of colon cancer postoperative chemotherapy can be given for stage III or “high-risk” stage II 
diseases, however, the level of evidence is lower for rectal cancer 84. 
National results of rectal cancer treatment in Sweden 
The report on rectal cancer from the Swedish Colorectal Cancer Registry with 98% national coverage displays the 
following results in 2013. Preoperative RT was given to 64.5% of patients treated with surgery and the five-year 
cumulative incidence of local recurrence was 5%. Three-year cancer-specific survival was 89.7% for stage I to III 
disease treated with curative intent, though 18.8% of these patients developed distant metastasis after three years. 
Current rectal cancer treatment offers good local control and room for improvement in systemic control. Chemo-
therapy is effective in treating microscopic disease and is currently tested in combination with short course RT as 
neoadjuvant treatment in the “Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Opera-
tion” (RAPIDO) trial 85. 
Organ preservation 
Preoperative treatment can result in complete disappearance of detectable cancer growth in the specimen. The fact 
of complete pathological response rose questions about the need of resection in these selected patients. In 2004 
Professor Angelita Habr-Gama, from the University of São Paulo School of Medicine, published the results of a 
wait-and-see policy in low rectal cancer 86. After preoperative chemoradiotherapy 71 patients not resected after 
complete clinical response were compared to 22 patients resected with complete pathological response. No pelvic 
recurrence was observed and two patients not resected developed an endorectal recurrence treated by local excision 
or brachytherapy. Rectal resection showed no overall or cancer-specific survival benefit. The patients not resected 
are meticulously followed with repeated digital, endoscopic and radiologic examinations challenged to discriminate 
between post-treatment fibrosis and residual/ recurrent cancer growth. A Dutch pilot study also found promising 
outcomes but large observational and randomized studies are to come 87 88. 
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Adverse effects of rectal cancer treatment 
The perioperative mortality is 2% after rectal cancer surgery and 11% to 12% develop an anastomotic leak or 
pelvic sepsis 89. The oncologic outcomes improved during the past decades and functional outcomes with an impact 
on life of cancer survivors have gained more attention. Resection of the rectum, localized in the posterior 
compartment of the narrow pelvis, has an impact on bowel function due to the loss of storage capacity. Even uri-
nary and sexual function may be affected. The widespread use of RT, associated with specific adverse effects, 
makes it difficult to differentiate between the negative impacts of surgery and RT on pelvic function. In the Stock-
holm I and II Trials the majority of postoperative deaths were due to cardiovascular disease and more common in 
patients treated with preoperative RT. After reduction of the target volume by changing from two-field to four-field 
RT technique the difference in mortality disappeared 90. The acute adverse events of short course preoperative RT in 
the TME Trial were limited to a slight increase of total number of postoperative complications, 100ml higher 
intraoperative blood loss and more perineal wound infections after APE 91. No effect on postoperative mortality was 
observed.  
Perineal wound healing after abdominoperineal excision
Wound healing after APE is complicated by several factors that may be more pronounced after extralevator APE 
due to the increased tissue loss of the pelvic floor. The remaining pelvic cavity can lead to small bowel displace-
ment with consecutive small bowel obstruction or perineal herniation. In women the vagina and the uterus are dis-
placed towards the sacrum resulting in decreased vaginal calibre and “cupping” of the upper vagina associated with 
vaginal discharge and dyspareunia 92. Primary closure of the defect of the pelvic floor is seldom possible and the 
perineal wound cavity is surrounded by irradiated tissue in an area keen to bacterial contamination. The frequency 
of wound problems after primary perineal wound closure increases from 15% to 30.2% in conventional APE and 
37.6% in extralevator APE if RT is added 93. Biological mesh closure of the pelvic floor may decrease perineal 
wound problems after extralevator APE and randomized trials comparing mesh closure to primary or gluteus max-
imus myocutaneous flap closure are going on. Additionally, patients treated with APE have to cope with a perma-
nent stoma associated with certain morbidity beside potential stigmata and taboos. Apart from inappropriate stomal 
site and early postoperative complications late adverse events such as stomal prolapse, stomal stenosis or 
parastomal herniation may occur 94. However, quality of life with a permanent stoma is not necessarily inferior 
compared to patients treated with sphincter-saving procedures 95. 
Low anterior resection syndrome 
Reconstruction of bowel continuity with anastomosis of the left colon and the remaining part of the rectum or anal 
canal after anterior resection results in problems regarding bowel function characterized by urgency, frequent bowel 
movements and occasional faecal incontinence 96. The low anterior resection syndrome score is a reliable and vali-
dated questionnaire to assess bowel function after anterior resection 97. Preoperative RT, short length of remaining 
rectum, anastomotic leakage, female gender and age over 64 years have a negative impact on severances of the 
anterior resection syndrome 98 99. Impaired bowel function is also related to restricted quality of life 100. The reason 
for urgency and frequent bowel movements might be physiological changes based on neural damages resulting in a 
hyperactive postprandial response of the neorectum 101. The colonic J-pouch showed improved functional outcomes 
compared to a straight anastomosis but was not better than the side-to-end anastomosis 102 103 104. The small bowel 
is also affected by treatment for rectal cancer with increased risk for postoperative obstruction due to adverse ef-
fects of surgery and/ or RT. Diarrhoea, bleeding and rarely malabsorption, necrosis or perforation are attributed to 
small bowel damage following RT 99. 
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Urinary function 
The negative impact on urinary function seems to be less pronounced and gradual improvement within six months 
might be expected 105. Injuries of autonomic nerves during pelvic dissection contribute to a greater extent than RT 
to negative effects on bladder function 106 99. Evaluation of urinary function with dedicated questionnaires in Danish 
women resulted in a frequency of 77% and 63% respectively for urgency and incontinence 107. The type of surgery 
was not related to the negative impact on urinary function and RT increased only voiding difficulties in these long-
term survivors. 
Sexual function 
The autonomic nerves of the pelvis gained a lot of attention during introduction of TME, as they are located close to 
the mesorectal fascia, the recommended plane of surgery. The hypogastric nerves unite the superior hypogastric 
plexus, containing sympathetic fibres anterior to the abdominal aorta, with the bilateral inferior hypogastric plexus 
or pelvic plexus at the pelvic sidewall. The inferior hypogastric plexus has connections with the sacral roots S2 to 
S4 containing parasympathetic fibres and proceeds in form of the neurovascular bundles to the pelvic organs. Re-
section of the superior hypogastric plexus/ nerves results in retrograde ejaculation in men 108. Unilateral resection of 
the inferior hypogastric plexus impairs penile erection. In women parasympathetic fibres from the inferior hypogas-
tric plexus mediate the increase of vaginal blood flow during sexual arousal leading to an increase of vaginal tran-
sudate with lubricating effect 109. Anatomy and physiology of structures important for orgasm in women are still a 
matter of debate 110. While male sexual dysfunction after rectal cancer treatment has been well described, consider-
ably less data have been published about the impact on women 111. Data from the Dutch TME Trial indicate that a 
majority of patients with resectable rectal cancer are sexually active at the time of diagnosis (79% of men, 52% of 
women) 112. Among women, 60% experienced an increase in general sexual dysfunction, dyspareunia and vaginal 
dryness. In men, problems with increased sexual dysfunction, erection and ejaculation were reported by almost 
75%. Radiotherapy and presence of a stoma was associated with increased sexual dysfunction in both sexes 113. The 
convenience in assessment of sexual response and the discovery of phosphodiesterase type 5 inhibitors (PDE5- 
inhibitor) might have contributed that data on erectile function and ejaculation dominate the available literature of 
sexual dysfunction after rectal cancer treatment. However, sexual health is more than erection and ejaculation in 
men. Physiologic, psychological and context-related factors (i.e. couple dynamics, sociocultural issues, abuse) 
should be considered in evaluation of sexual function according to the Standards Committee of the International 
Society for Sexual Medicine. A physiologic sexual response requires integrity of hormonal, vascular, nervous, mus-
cular, connective and immune systems and classification of sexual disorders involves desire, arousal, orgasm and 
pain. Studies assessing sexual function in patients with rectal cancer should also account for the high prevalence of 
sexual complaints in the general population of comparable age 114 115. Several questionnaires assessing sexual dis-
orders exist but it is not clear if the existing instruments are able to reliably assess the impact of rectal cancer treat-
ment on sexual function 116. 
The positive effect of PDE5-inhibitors in men with vasculogenic erectile dysfunction is well documented. The ben-
efit of PDE5-inhibitors in treatment of erectile dysfunction caused by rectal cancer treatment is not well established 
and might be impaired as surgery puts penile innervation at risk and RT may induce penile fibrosis. Further it has 
not been studied at which time-point PDE5-inhibitor treatment should be initiated. Currently three PDE5-inhibitors 
(sildenafil, vardenafil and tadalafil) with different pharmacokinetics are available. Sildenafil completely reversed or 
satisfactorily improved erectile dysfunction in a randomized placebo-controlled trial among men 5 years after rectal 
resection due to rectal cancer or inflammatory bowel disease 117. Rehabilitative and protective effects of PDE5-
inhibitors on penile function are discussed for men undergoing nerve-sparing radical prostatectomy for prostate 
cancer, but there is still little clinical evidence 118. The lack of spontaneous erections and consecutive decreased 
oxygenation of the cavernous tissue during the state of erectile nerve dysfunction may be a potential mechanism 
leading to long-term erectile dysfunction. In men after radical prostatectomy the medication with 5mg tadalfil once 
daily was more effective than 20mg tadalafil on demand to restore erectile function during the first 9 months post-
operatively 119. This randomized controlled trial failed to show a clear advantage of early continuous PDE5-
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inhibitor intake on postoperative erectile function but the postoperative decrease in flaccid penile length, a conse-
quence of penile fibrosis, was significantly lower. 
The effects of PDE5-inhibitors have also been tested in treatment of female sexual dysfunction with conflicting 
results. According to a review from 2009, some trials showed a beneficial effect especially for women with under-
lying conditions such as multiple sclerosis, diabetes, spinal cord injury, and use of antidepressant medications 120. 
The results of self-reported effects on female sexual function are mixed despite reproducible significant physiologic 
effects on genital vascular congestion. The combination of testosterone and PDE5-inhibitors on demand might be 
promising for treatment of hypoactive sexual desire disorders in women 121. 
As PDE5 inhibition results in smooth muscle relaxation and increased pelvic blood perfusion, several other effects 
may be of interest in patients treated for rectal cancer 122. Sildenafil improved the bursting pressure of colonic anas-
tomosis in the presence of intra-abdominal infection and reduced peritoneal adhesions in rats 123. PDE5-inhibitors 
enhanced and prolonged the induction of DNA damage in chemotherapy for gastrointestinal cancer 124. Even posi-
tive effects of PDE5-inhibitors on skeletal muscle function are reported 125. 
Specific late adverse effects of radiotherapy 
Specific late adverse effects attributed to RT are increased risk of secondary cancers, pelvic or femoral insufficien-
cy fractures and thromboembolic disorders 99. Many of these results were observed in studies with old RT technol-
ogy and may decrease or even disappear with the use of more refined RT technology 61. The acute and late effect of 
RT on ovarian or testicular function may have an impact on fertility and hormone homeostasis 106. The sensitivity of 
the ovaries to irradiation and chemotherapy results in high risk of impaired fertility and premature menopause 126. 
Radiation doses over 24 Gy result in permanent ovarian ablation. This could be of importance even in postmeno-
pausal women as the ovaries produce half of the testosterone in women 127. The effects on testicular function are 
discussed later. In analogy to the findings in RT for prostate cancer exposure of the neurovascular bundles and the 
penile base to radiation may result in impaired erection due to vascular and nervous injuries 128. Characteristic vagi-
nal findings after RT are atrophic pale mucosa and fibrosis with consecutive loss of lubrication and elasticity or 
even narrowing and shortening of the vagina leading to dyspareunia or impossibility of penetrating intercourse 129. 
The genital organs are not routinely included in normal tissue at risk of radiation damage during treatment planning 
of RT 130. The positive effects of RT on oncologic outcomes and the potential of complete response enabling organ 
preservation are in contrast to the negative effects on postoperative and functional outcomes. So the future use of 
RT in rectal cancer treatment is debated 131. 
Basics of radiation biology
The basics of radiation biology are retrieved from the handbook for teachers and students published by the Interna-
tional Atomic Energy Agency 132.  
Electromagnetic radiation (e.g. X-rays or γ-rays) is indirectly ionizing as energy of photons, left behind during pas-
sage through biological tissue, produces secondary electrons (charged particles), which results in biological effects. 
Particulate radiation (e.g. α and β particles, protons, neutrons) also causes ionization and specially the charged ele-
mentary particles cause intense damage as they lose their energy within short distance of tissue. The density of 
energy deposition in the tissue is called Linear Energy Transfer (LET) and is important as the biological effect de-
pends on LET. Electromagnetic radiation has generally lower LET than particulate radiation. 
The radiation dose is the amount of energy absorbed per mass of tissue measured in the units of Gray (1 Gy = 1 
Joule/kg). The equivalent dose is calculated by multiplying the absorbed dose with a weighting factor (quality fac-
tor) and has the units of Sievert (Sv). The absorbed and equivalent doses for low LET radiation are equal as the 
quality factor is one (1 Sv = 1 Gy). 
The loss of energy of radiation after physical interaction leads to ionization and excitation of atoms and molecules, 
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which may convert into free radicals. When ionizing radiation energy is deposited in DNA or lipids of the cell 
membrane the effect is direct. Radiation energy can also be deposited in cellular water leading to indirect effects by 
water radiolysis. Certain compounds may scavenge radicals of water radiolysis and act against the indirect effects 
of radiation. A dose of 1 to 2 Gy induces about 1000 base damages, 1000 single strand breaks and 40 double strand 
breaks in the DNA of a single cell. The double strand breaks play a critical role for cell killing but different 
enzymatic DNA repair mechanism can limit the effects of these radiation induced damages. The loss of reproduc-
tive integrity (i.e. apoptosis, necrosis, mitotic catastrophe, induced senescence) is seen as equivalent for cell kill by 
radiation. In contrast to apoptosis cell necrosis is accompanied by an inflammatory response. 
Survival of cells during radiotherapy 
Radiosensitivity of cell populations is measured by the proportion of cells surviving irradiation with intact ability to 
undergo more than five to six cell divisions. Survival curves plot surviving fraction against radiation dose and the 
most common model to describe the decline of survival by increasing dose is the linear-quadratic model. 
Radiosensitivity differs during the cell cycle and cell 
survival is increased if the same dose is given in two 
fractions with more than two hours in between due to 
cellular repair. The time for full cell repair takes six to 
eight hours or even longer. The repair during delivery 
of radiotherapy is negligible in external beam RT with 
a dose rate of 1 to 5 Gy/min but significant in brachy-
therapy with 1.6 to 150 cGy/min. Oxygen and pyrimi-
dine analogues (e.g. 5-fluorouracil administered during 
long course RT) are examples of molecules that in-
crease radiosensitivity. 
Figure 3. A survival curve using the standard LQ formu-
la e-(αD+βD2) where α = 0.2 and α/β = 3. The components
of cell killing are equal where the curves e-αD and e-βD2
intersect. This occurs at dose D = α/β = 3 Gy in this 
example. (www.eyephysics.com/tdf/models.htm) 
Tumour control 
The growth of a solid tumour is the result of proliferation of tumour cells and development of supporting stroma 
and vasculature by angiogenesis. The effect of RT on these cells is the tumour response to irradiation. Complete 
tumour control by RT means that all cancer stem cells, defined by unlimited proliferative capacity, must be killed. 
Hypoxia and apoptosis of endothelial cells are factors influencing the 
microenvironment of tumour cells and may reduce radiosensitivity of 
tumour cells. Theoretically the required dose for tumour control de-
pends on the number of cancer stem cells, estimated from the tumour 
size, and their radiosensitivity. The expected level of cell survival for a 
given dose can be predicted by a Poisson distribution and shows a 
sigmoid relation to dose with the slope reflecting radiosensitivity. 
Figure 4. Sigmoid dose-response curves showing the relationship 
between increasing dose and tumour control probability and normal 
tissue complication probability. The therapeutic ratio is determined by 
the horizontal separation between the curves 133.
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Fractionated radiotherapy 
Fractionation of the radiation dose enables RT with higher doses as repair of radiation damages and proliferation of 
surviving cells can occur between fractions. The repair capacity of normal tissue is greater compared to tumour 
tissue, which favours fractionated RT. The effect of RT on biological tissue depends on the proliferation rate of the 
tissue and becomes evident during cell divisions after irradiation. The loss of function in renewal tissues like the 
bone marrow or the mucosa of the gastrointestinal tract correlates with the loss of proliferation activity of stem 
cells. The acute adverse effects appear within few weeks. Late responses are the result of damages to parenchymal 
cells with low proliferation or damages to supporting stroma/ vasculature. Late adverse effects become evident 
months or years after RT and often confine the total dose of RT regimens. 
Biological factors affecting the response of tumours and normal tissues in fractionated RT are also called the five 
“R”: Repair, repopulation, redistribution, reoxygenation and radiosensitivity. 
The capacity to repair radiation damages is indicated by the shoulder of a cell survival curve and depends on the 
type of tissue. Repopulation occurs between fractions due to proliferation of surviving cells and may increase spe-
cially in early-responding normal tissue and tumours. Radiosensitivity differs during the phases of the cell cycle and 
surviving cells redistribute to more sensitive phases enhancing the effect of fractionated RT. Hypoxia increases 
radioresistance and surviving cells become reoxygenated between fractions hence also favouring the fractionated 
RT. 
The biological effect of different fractionation schedules can be compared with models based on the linear-
quadratic equation. It is assumed that every fraction has equal effect and that isoeffective schedules result in the 
same survival fraction. The constant [α/β] for a particular tissue can be determined by comparison of two isoeffec-
tive regimens with different fractionation to predict other isoeffective schedules. The parameter α defines the initial 
slope of the survival curve and parameter β defines the curvature of the curve. The values of the constant [α/β] are 
in the range of 2 to 4 Gy for late responding tissues and 8 to 12 Gy for early responding tissues. Many tumours have 
[α/β] values similar or higher to those of early responding tissues. The duration of a fractionated schedule is not 
considered in the LQ model, which is an important limitation in early responding tissues and tumours characterized 
by high proliferation. The equation to calculate the biologically effective dose (BED) of early responding tissues 
includes therefore a repopulation term that can be omitted for calculation of BED in late responding tissues 134. 
BED = log cell kill – repopulation term 
BED = n*d(1 + d/[α/β]) – loge2*(T-Tk)/α*Tp 
n = number of fractions 
d = dose per fraction 
T = treatment time 
Tk = time to start of delayed repopulation 
Tp = cell doubling time 
This formula is useful to describe BED of different fractionation schedules for tissues exposed to radiation doses 
resulting in cell kill. 
Planning and delivering of external beam radiotherapy 
Current external beam RT uses high-energy electromagnetic radiation (X-rays) from a linear accelerator. The elec-
tron gun produces free electrons that are sent to the accelerator tube. The high-frequency electromagnetic waves in 
the tube accelerate the electrons that ride on top of electromagnetic waves and boost their energy to the desired 
level. The beam exiting the accelerator is then diverted and sent to the treatment head. Blocks, filters and multileaf 
collimators shape the beam before leaving the gantry that can rotate 360° around the patient. The precise position-
ing of the radiation source and the patient are important to deliver accurate RT. 
During treatment simulation the patient is immobilized on the treatment couch to acquire a planning CT and to 
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Hypogonadism
Testosterone in men 
The pulsatile release of gonadotropins from the pituitary is the result of gonadotropin-releasing hormone (GnRH) 
pulses occurring every 60 to 90 min in the hypothalamus 135. Follicle-stimulating hormone (FSH) and intratesticular 
testosterone (T) stimulate spermatogenesis by acting on Sertoli cells. Luteinising hormone (LH) increases the T 
synthesis in the Leydig cells of the testes. Adult men after normal puberty produce 3 to 10 mg of T per day corre-
sponding serum T levels of 10.4 to 34.7 nmol/l 136. The diurnal variation with a decrease during daytime in serum T 
is most prominent in men younger than 45 years 137. Serum T can be assessed at any time before 2 p.m. in men 
older than 45 years without misleading results. In men from the north of Norway seasonal variation in serum T with 
a small peak in February and a prominent peak in autumn have been registered 138. Glucose load and physical activ-
ity may also have an impact on serum T levels 139. 
In plasma approximately half of the serum T is tightly bound to sex hormone-binding globulin (SHBG) and not 
available for cells. The remaining T is loosely bound to proteins such as albumin and 1% to 2% of T is free in 
plasma. The non-SHBG-bound T or bioavailable T is freely dissociated and participates in tissue interaction 140. 
Thus, conditions that influence SHBG may affect bioavailable T. SHBG increases with age, hyperthyroidism, liver 
disease and decreases with obesity, diabetes mellitus and glucocorticoid use. The presence of other steroids in high 
concen-tration and potentially very low levels of T in children, women and hypogonadal men complicate the 
measurement of T plasma levels 141. The reference methods for direct measurement of free T and bioavailable T, 
equilibrium dialysis and ammonium-sulphate precipitation respectively, are technically challenging and not widely 
available. The radioimmunoassay is expensive, time intensive and creates radioactive waste. So enzyme 
immunoassays are widely used to measure T. They often overestimate low concentrations and have a considerable 
inter-laboratory variability 142. Mass spectrometry is actually promoted as the most accurate method for clinical 
steroid measurement. However, inter-laboratory variability is still a problem and validated immunoassays seem 
sufficient to detect subnormal T concentrations for diagnosis of hypogonadism in men 143. 
To evaluate men with signs of hypogonadism the measurement of serum T in a morning sample with a validated 
immunoassay or mass spectrometry is recommended. Low serum T levels should be confirmed with a second blood 
sample due to considerable variation even in young healthy men 144. In addition to serum T the concentrations of 
SHBG and albumin should be measured in the second sample to calculate bioavailable T and free T based on equa-
tions 145. LH and prolactin measurement in the second sample allow for differentiation between primary and sec-
ondary testicular failure as explained below. 
Testosterone acts directly via androgen receptors in the cytoplasm and nucleus of target cells. Polymorphism of the 
androgen receptor, for example different length of CAG repeats in exon 1 of the androgen receptor gen, may influ-
ence the androgen action of T in several tissues 146 147. The 5α-reductase of the prostate, external genitalia and skin, 
converts 5% to 8% of total T to the locally active metabolite dihydrotestosterone. A small amount of T (0.5%) is 
converted to oestradiol by aromatase in adipose tissue and liver. The joint action of T and oestrogens in adult men 
suppresses accretion of adipose tissue and bone loss and is important for maintaining normal libido and erectile 
function 148. 
The adrenal cortex also produces androgens such as dehydroepiandrosterone (DHEA), its sulphate and andros-
tenedione. These androgens can be converted into T, however, serum T levels drop by 95% after surgical androgen 
deprivation by orchiectomy to levels below 0.69 to 1.73 nmol/l 149. So the adrenal gland cannot compensate a sig-
nificant decline in serum T in men due to pathologies of the hypothalamic-pituitary-gonadal axis. Adrenal andro-
gens may become important during androgen deprivation in advanced prostate cancer. Observations under this 
condition indicate that the adrenocorticotropic hormone (ACTH) and LH play a role in regulation of adrenal andro-
gen synthesis 149. 
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The hypothalamic-pituitary-gonadal axis 
In men disruption of the hypothalamic-pituitary-gonadal axis leads to hypogonadism, sometimes referred to as tes-
tosterone deficiency. Primary testicular failure results in primary hypogonadism characterized by low T levels, 
impaired spermatogenesis and elevated gonadotropins. Common causes of testicular failure are Klinefelter´s syn-
drome (47, XYY), testicular tumours, Mumps-related orchitis, radiation, chemotherapy, testicular trauma and tor-
sion. Low T levels, reversible reduced spermatogenesis and low or inappropriately normal gonadotropins character-
ize secondary hypogonadism. Apart from isolated congenital gonadotropin deficiency acquired conditions such as 
hyperprolactinaemia, pituitary damages, systemic disease, obesity, 
diabetes, eating disorders, excessive exercise or medications can 
lead to hypogonadotropic hypogonadism. Serum T levels below 
the lower reference limit of young adults are not uncommon in 
men over age 60 and due to a yearly decline in serum T of about 
1% after the age of 20 to 40 years. Names like andropause or male 
climacterium generate confusion with the physiologic condition of 
menopause in women and should be avoided. Late-onset hy-
pogonadism (LOH) describes a mixed form of hypogonadism 
observed in older men with combined primary and secondary 
testicular failure 142. The serum T levels are low and gonadotropin 
levels indicate whether primary testicular or hypothalamic-
pituitary failure dominates. Hypogonadism due to androgen recep-
tor defects or 5α-reductase deficiency result in androgen insensi-
tivity syndromes and are rare. 
Figure 7. Hypothalamic-pituitary-gonadal axis
(www.dsdgenetics.org; reprinted with permission)
Signs of hypogonadism 
Prepubertal onset of hypogonadism results in incomplete sexual development (micropenis, small testes and pros-
tate), infertility, eunochoidal proportions (delayed epiphyseal fusion), gynaecomastia, high-pitched voice and de-
creased body hair, bone and muscle mass. Adult men that develop hypogonadism after normal puberty have normal 
skeletal proportions, penile length, voice and prostate size. Postpubertal onset of hypogonadism affects sexual 
function, body composition and mood. The clinical symptoms occur at different levels of serum T 150. 
Clinical manifestations suggestive for postpubertal onset of hypogonadism: 
Sexual function Decreased sexual interest/ libido 
Decreased frequency of spontaneous (morning) erections 
Erectile dysfunction 
Body composition Decreased body hair/ shaving 
Visceral obesity and gynaecomastia 
Decrease in lean body mass and muscle strength (sarcopenia) 
Decrease in bone mineral density 
Insulin resistance, metabolic syndrome, hot flushes, sweat 
Mood Decreased energy, motivation, concentration and memory 
Fatigue, dysthymia, depressive thoughts, anger 
Sleep disturbances 
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Testosterone-replacement therapy 
Testosterone-replacement therapy (TRT) is an option in hypogonadal men without signs of hormone-responsive 
tumours (prostate, breast), severe lower-urinary-tract-symptoms, haematocrit > 50%, severe sleep apnoea or uncon-
trolled congestive heart failure 136. Sexual motivation, erectile function and number of successful intercourses in-
creases with TRT in men with serum T levels < 12 nmol/l but the impact on overall sexual satisfaction are conflict-
ing and the effect of TRT declines over time 159. The combined treatment with PDE5-inhibitors and testosterone 
restores erectile function in hypogonadal men more effectively than monotherapy with PDE5-inhibitors or testos-
terone 160. Improvement of sexual function under TRT is most marked in less obese men and those without simulta-
neous depression 161. Lumbar spine bone-mineral density increases with intramuscular but not with transdermal 
TRT and the effect on the femoral neck is not conclusive 162. A meta-analysis summarized the effect on body com-
position in men between 50 to 78 years of age 163. The body weight did not change but on average the fat-free mass 
increased by 1.6 kg and the total body fat decreased by the same amount. Muscle strength tended to improve and 
total cholesterol decreased. Low T and sexual dysfunction is a common finding in obese men with metabolic syn-
drome and diabetes 164. TRT may improve the risk profile of cardiovascular diseases in this group but the results of 
TRT in men with diabetes or metabolic syndrome are conflicting 165. In depressed patients with hypogonadism TRT 
was antidepressive and the route of administration could be important 166. In men over age 60 improvements of 
memory have been observed under TRT and the positive effect on verbal memory seems to be related to aromatisa-
tion of T to oestradiol 167. The treatment monitoring includes assessment of erythrocytosis by haematocrit and pros-
tate by digital rectal examination and PSA to detect adverse effects of TRT. The evidence regarding benefits and 
risks of TRT is mainly based on small studies with suboptimal design and duration, so the results of on-going ran-
domized studies are awaited with interest 142. 
Body composition 
Models of body composition assessment 
Direct measurement of body fat is despite a variety of methods for assessment of body composition not 
possible 168. The four-compartment (4C) model measures the chemical composition of the body and is often 
considered the reference method for assessment of body composition. The model uses minimal assumptions and 
quantifies the amount of water, mineral, protein and fat. Total body water and bone mineral are measured 
directly using isotope dilution of deuterated (heavy) water and dual energy X-ray absorptiometry (DEXA). Total 
body density is calculated after assessment of total body volume by subtraction of underwater weight from 
weight in air or alternatively by whole body plethysmography. The amount of fat and protein, the 
unmeasured fraction, can be calculated applying assumed densities of fat, water, bone mineral and protein 169.
The two-compartment (2C) model separates the body into fat and fat-free/ lean mass (i.e. total body water, 
bone mineral and proteins). The accuracy of such a model has been questioned as it is based on the 
assumption of con-stant and fixed hydration/ bone mineralisation ignoring age- and sex-related differences. 
Skinfold thickness assessment and bioelectric impedance analysis are cost effective and widely available 
methods to assess the two-compartment model but accuracy is limited 170.
The three-compartments (3C), fat, bone mineral and soft-lean mass, can be assessed by DEXA, the method 
of choice to quantify bone mineralisation. This X-ray based method assumes constancy of water and lipid content 
for skin, muscle and bone, which in vivo may vary.
Anthropometric methods based on weight such as the BMI cannot distinguish between fat and muscle and 
problems arise in individuals with shape different from the norm. Considering sitting height or leg length 
can improve the value of these indices 170. 
Cross-sectional imaging techniques, CT and MR, can also be used to assess body composition on the tissue level. 
Different attenuation of adipose tissue, skeletal muscle and bone enable tissue delineation on two-dimensional slic-
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durance exercise. In obese men accumulation of intracellular lipid droplets was related to insulin resistance. The 
increment of intracellular fat in skeletal muscle is also called myosteatosis and leads to changes in muscle attenua-
tion detectable on CT or MR 181. In a large cohort with patients treated for respiratory or gastrointestinal tract ma-
lignancies sarcopenia and low attenuation of psoas muscle were independent predictors for lower survival 182. 
Testosterone and skeletal muscle 
The anabolic effect of androgens on skeletal muscle is the reason for the popularity among abusers 183. Multiple 
mechanism are involved in the androgen action on muscle, which results in promotion of muscle protein anab-
olism and differentiation of pluripotent stem cells toward myogenic lineage 184. Apart of this myotrophic effect of 
endogenous and exogenous T, training enhances the T effect on skeletal muscle. Physical exercise increases the 
expression of androgen-synthesizing enzymes (e.g. 5α-reductase) in the skeletal muscle that promote synthesis of T 
and dihydro-T from circulating DHEA resulting in intracrine androgen action 185. Several studies report an associa-
tion of endogenous T levels and muscle mass, muscle strength and physical function but these results are not con-
sistent and often restricted to free or bioavailable T 186.  The supplementation of T in young and older men results in 
a dose-dependent increase in muscle mass and a reciprocal decrease in fat mass 187 188 189. Improvements in muscle 
strength are modest especially for near physiologic TRT 186 190. An interesting alternative to supraphysiolog-ic T 
replacement aiming to increase muscle mass and strength are selective androgen receptor modulators with 
myotrophic effect in absence of androgenic effects on prostate, hair and skin 191. Findings in androgen receptor 
knockout mouse models suggest that androgens are involved in growth and maintenance of skeletal muscle mass as 
well as muscle development and function 192. In animal studies the androgen sensitivity of skeletal muscle was 
often investigated in muscles supporting masculine reproductive functions 193. Examples are copulatory perineal 
muscles of rodents, vocal muscles used in mate-attraction or limb muscles in birds that display spectacular 
athleticism dur-ing courtship. In pigs the androgen effect on skeletal muscle growth differs among muscle groups 
194. Androgen deprivation therapy in men with prostate cancer may result in more pronounced loss of muscle mass 
and strength of the upper compared to the lower extremity 195. Differences in androgen receptor expression observed 
in trapezius and vastus lateralis muscle of humans may explain this variation in androgen sensitivity of different 
skeletal muscle groups 196 147. 
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AIMS OF THE THESIS
The general aim of the research project was to investigate the effects of contemporary rectal cancer treatment on 
testicular function and the consecutive impact on sexual function and quality of life. The available literature on 
radiation exposure of the testes during radiotherapy and testicular function in men treated for rectal cancer was 
systematically reviewed in Paper I to summarize current knowledge and generate relevant hypotheses. The 
reviewed data served as basis to design and implement a cohort study assessing identified research questions. In the 
present thesis the following specific aims are addressed: 
Paper II 
To calculate the testicular dose during contemporary radiotherapy for rectal cancer based on planning CT and to 
evaluate the difference between planned and delivered testicular dose. 
Paper III 
To assess the acute effects of preoperative radiotherapy for rectal cancer on androgen levels. 
Paper IV 
To investigate the association between longitudinal changes in testosterone levels and body composition in men 
treated with preoperative radiotherapy for rectal cancer and to evaluate the clinical value of such an association to 
support decision-making in men with testosterone levels in the grey zone of hypogonadism. 
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Review of Literature 
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REVIEW OF LITERATURE
Paper I 
Methods
In cooperation with a librarian, we assessed PubMed, Embase, and Cochrane applying a search design using the 
MeSH-term “Rectal Neoplasms” in combination with: “Sexual Behaviour”, “Sexual Dysfunctions, Psychological”, 
“Sexual Dysfunctions, Physiological”, “Gonadal Hormones”, “Radiotherapy”, “Radiation”, “Quality of Life”, 
“Spermatozoa” and “Testis”. Original articles providing data on testicular radiation exposure, testicular function or 
the impact of hypogonadism on sexual function and quality of life in men with primary rectal cancer were included. 
No restrictions regarding study design were applied. 
Results
The search strategy resulted in inclusion of three cohort studies and seven case series out of 188 identified abstracts. 
No randomized control trials or systematic review were identified. According to the “New levels of evidence” pub-
lished by the Centre for Evidence-Based Medicine (University of Oxford; http://www.cebm.net) regarding treat-
ment harms the evidence is at level 4 (step 4). The lack of high-quality studies and the heterogeneity of the identi-
fied publications precluded a systematic data synthesis. 
Testicular radiation exposure during radiotherapy for rectal cancer
Six studies reported the testicular radiation exposure during RT for rectal cancer 197 198 199 200 201 202. The testicular 
dose (TD) was estimated either by scrotal dosimeters, by treatment planning software based on CT or by 
equations derived from phantom measurements. The mean cumulative TD varied between 1.24 Gy and 8.4 Gy 
(range 0.06 to 13.7 Gy) for external beam RT. This corresponds to 3% to 17% of the prescribed dose. 
Table 2. Testicular radiation exposure during radiotherapy for rectal cancer
Radiotherapy schedule Cumulative testicular dose 
First author Type Dose per fraction Prescribed dose Mean Range 
Dueland 197 EB 2 46-50 8.4 3.7 – 13.7 
Piroth 198 EB 1.8 50.4 1.6 0.98 – 3.19 
Hermann 199 EB 2 50 + 6 3.56 0.7 – 8.4 
Mazonakis 200 EB 1.8 45 1.9 1.1 – 2.8 
Yau 201 EB 
BT 
1.8 
6.5 
45-50.4
26 
1.24 
0.27 
0.06 – 7.8 
0.14 – 0.65 
Yoon 202 EB 1.8 50.4 + 3.6 4* 1.5 – 8.9 
Dose values in Gy, EB=External beam, BT=Brachytherapy, * Median cumulative testicular dose 
The distance between the testes and the lower radiation field edge, the patient thickness along the beam axis and the 
photon energy were factors influencing TD. Treatment field elongation and wedged lateral beams were of minor 
importance 203 200. 
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In most studies the patients were treated in the prone position to reduce the irradiated small bowel volume. In order 
to enhance this effect, a single-hole belly board (SHBB) was used 198. The double-hole belly board (DHBB) with an 
additional hole for the testes was developed to decrease the testicular dose. The number of radiation fields, the posi-
tioning devices (SHBB vs. DHBB) and the height of the tumour influenced the testicular dose significantly 204. A 
conventional gonad shield based on the placement of a lead block on a shadow tray reduced the TD by 27–41%. 
With the round gonad shield made of 1.27 cm thick lead, a reduction of 66–74% was seen 200. The lowest propor-
tion of the prescribed dose (0.5–2.5%) was delivered to the testes using a high-dose-rate brachytherapy for tumours 
located in the lower and middle third of the rectum. The patient was in lithotomy position and using a jockstrap to 
move the testes away from the target volume 201. 
Spermatogenesis in men with rectal cancer 
No reports on semen analyses in men treated for rectal cancer were identified. 
Testosterone levels in men treated with radiotherapy for rectal cancer
The use of RT decreased serum T levels in all studies when comparing pre- to posttreatment levels or patients with 
and without radiotherapy. The reduction in serum T was statistically significant in three of four studies and ob-
served within two months after RT and persisted after follow-up of at least 3.9 years 197 205. 
Table 3. Serum testosterone in men treated with external beam radiotherapy for rectal cancer 
Mean (± SD) serum testosterone (nmol/l) Frequency of serum testosterone < 8 nmol/L (%) 
First author Before/without RT After/with RT P value Before/without RT After/with RT 
Dueland 197 14.4 (4.9) 10.6 (4.3) 0.001 8 35 
Hermann 199 0.07 40 70 
Bruheim 205 13.4 (5) 11.1 (4.7) <0.001 10 27 
Yau † 201 0 
0* 
17.6 
2.7* 
Yoon ‡ 202 15.4 (6.1) 12.1 (4.6) <0.001 
SD=standard deviation, RT=preoperative radiotherapy 
* Brachytherapy, † Only patients with normal baseline hormonal values, ‡ Only patients reporting sufficient erectile function for intercourse included 
The frequency of low serum T (< 8 nmol/l) before RT or among men treated with surgery alone was 0% to 
40%, increasing to 17% to 70% after RT. From these data, an absolute risk increase of 17% to 30% to have low 
serum T after RT can be deducted. In the study with the largest number of patients (N = 290), the relative risk 
for low serum T was 2.7 (95% CI 1.6 to 4.7; p<0.001) four years after RT 205.
In multiple regression analyses, a low radiation field edge and the use of a two-field technique were risk factors for 
low T levels 205. No significant effect was found for time since treatment, treatment position (prone vs. supine), 
chemotherapy (5-fluorouracil, leucovorine), or the timing of radiotherapy (pre- vs. postoperative). External beam 
RT with higher testicular doses resulted in a trend to lower T levels compared to brachytherapy 201. 
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Testosterone levels and sexual function in men with rectal cancer 
Based on the Norwegian Rectal Cancer Registry, one publication assessed serum T levels and sexual function with 
the International Index for Erectile Dysfunction (IIEF). The prevalence of moderate to severe erectile dysfunction 
was 86% in patients treated with RT compared to 55% treated with surgery alone (P < 0.001) 206. Age, RT and low 
serum T (< 8 nmol/l) were related to moderate-to-severe erectile dysfunction in the multivariate analysis. Men 
treated with RT also had significantly lower scores for orgasmic function and overall satisfaction with sex life. 
Discussion 
The studies investigating the TD during RT for rectal cancer and the effects on testicular function were sparse with 
low level of evidence. Systematic reviews or randomized controlled trials were lacking and the two population-
based cohort studies could analyse less than 60% of the eligible study population 205 207. The sample size of the 
other stud-ies was limited and power calculations were not published. The TDs were measured with different 
methods (i.e. scrotal dosimeters, treatment planning system or phantom-derived equations) resulting in dose values 
that represent the dose of a certain point of the scrotal skin (i.e. scrotal dosimeters) or the mean dose of the testicular 
volume (i.e. treatment planning system). The prescribed dose of RT, the RT technique (e.g. external beam vs. 
brachytherapy, number of fields, beam energy) and the time of RT (pre- vs. postoperative) varied between the 
studies. The methods of testosterone measurement could not be identified in three publications 199 201 202 and was 
different in the remain-ing two studies 197 205. In addition the baseline measurement of T was after surgery in the 
longitudinal study with postoperative RT 202. Yau et al. excluded men with abnormal androgen profiles 201. These 
methodical aspects lead to heterogeneity of the reported outcomes and imply a risk for bias that resulted in the 
decision not to perform a quantitative synthesis of the results. 
Testicular dose during radiotherapy for rectal cancer
The accuracy of the methods to assess the TD was not reported. According to Piroth et al., the variation of TDs 
measured by dosimetry was substantial 198. Different positions of the testes or dislocation of the scrotal dosimeters 
during the treatment session were mentioned as possible reasons. Gonadal shields could reduce TDs substantially 
200. Although they should be used with caution as they can induce cremaster reflex that decreases the distance be-
tween the lower radiation field edge and the testes. Gonadal shields located in the field of radiation produce second-
ary electrons that increase TD 208. 
Effects of testicular dose on germinal epithelium 
A single dose of 4–6 Gy reduced the number of spermatozoa significantly in healthy prisoners and time to complete 
recovery of spermatogenesis was dose dependent 209. A single-dose exceeding 6 Gy likely caused permanent azoo-
spermia 210. Testicular doses between 0.2 to 0.7 Gy during fractionated RT for Hodgkin’s disease caused a transient 
dose-dependent decrease in sperm concentration and a return to normospermia within 1 to 2 years 211. No recovery 
of spermatogenesis was found after TDs of 1.4 to 2.6 Gy in eight men treated with fractionated RT for testicular 
seminoma, while two men with TD of 1.2 Gy returned to normospermia 212. Similar findings were reported in 11 
men that received fractionated pelvic radiation with TDs between 1.18 to 2.28 Gy 213. During the follow-up period 
of 35–107 weeks, six men remained azoospermic, three recovered to oligospermia, and two returned to normo-
spermia. The threshold of fractionated RT inducing permanent azoospermia may be a cumulative TD around 1.2 to 
1.4 Gy. 
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Effects of testicular dose on Leydig cells 
The significant increase of LH with maintained T levels after single doses above 0.75 Gy and fractionated doses 
above 2 Gy indicate a negative yet compensated impact on Leydig cell function 209 214. A mean TD of 2.07 Gy in 
men treated with external beam RT for prostate cancer patients resulted in a significant decrease of serum T levels 
after three months, which, however, was not considered to be of clinical relevance 215. In contrast a mean TD of 
1.24 Gy during RT for rectal cancer resulted in biochemical hypogonadism (serum T < 8 nmol/L) in 15.5% of men 
with normal pretreatment T levels 201. So the results of studies that assessed the effect of pelvic RT for other malig-
nancies cannot be compared directly with results in men treated for rectal cancer. 
The majority of the studies included in this review do not report symptoms or risk factors related to hypogonadism. 
Only the Norwegian study found an association between low serum T (< 8 nmol/l) and moderate-to-severe erectile 
dysfunction 206. 
Conclusion 
Patient care 
This review suggests an increased risk of infertility and hypogonadism in men treated with RT for rectal cancer. 
Patients should get this information before start of RT to enable semen cryopreservation if requested and physicians 
should be alert to screen clinically for signs of hypogonadism. 
Research 
This review generates several hypotheses for further research. The testes are exposed to direct and/ or scattered 
radiation during RT for rectal cancer but the accuracy of TD calculation based on planning CT to estimate the de-
livered TD during all treatment fractions is not known. The acute and late effects of RT on testicular function may 
be related to a posttreatment decline in androgen-dependent physiological/ psychological functions and infertility. 
A dose-response relationship between TD and the effects of RT has not been established. The effects of hypogonad-
ism on quality of life have not been assessed in men with rectal cancer and semen analyses are lacking. 
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SUBJECTS AND METHODS
Cohort study 
Hypothesis
The testicular radiation exposure has acute and late adverse effects on testicular function resulting in an increased 
risk of transient or permanent infertility and hypogonadism with a relevant impact on patient reported outcome 
measures (PROM) in men treated with RT for rectal cancer. 
Study design 
Based on the findings of the review article (Paper I) we designed a cohort study with prospective data collection 
and preoperative RT as exposure. The exposure status was defined at the pre-therapeutic MDT conference prior and 
independent to any assessment of outcome measures. Serum T was chosen as the primary endpoint and spermato-
genesis, sexual function and quality of life were secondary endpoints. 
Power calculation 
The sample size of the exposed group was estimated under the assumption of a longitudinal decline in mean serum 
T of 3 nmol/l (standard deviation 6.5nmol/l) during the first two years after rectal cancer treatment with two-sided 
confidence intervals of 0.95 (1-alpha) and a minimal power of 0.80 (1-beta). The power of this setting exceeded 
0.80 with 40 pairs of observations. The proposed sample size was 100 considering that two thirds are given pre-
operative RT and one third is lost to follow up. 
Men with rectal cancer stage I to III and scheduled for rectal resection were eligible if they were over age 18, 
fluent in Swedish and had given informed consent. 
Exclusion criteria: Planned local excision of rectal cancer 
History/ evidence of urogenital cancer 
History of pelvic radiation for other diseases 
Androgen deprivation therapy, T replacement, androgen abuse 
Men treated with preoperative RT were assigned to the exposed group and men treated with surgery alone to the 
unexposed group. 
Study participants and setting
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Eighteen months after start of inclusion, less than 10% of the participants were treated with surgery alone . To 
increase the sample size of the unexposed group, men with prostate cancer stage I to III and scheduled for robot-
assisted prostatectomy were deemed suitable to paricipate, if they met the study criteria regarding age, command of 
language and informed consent. 
Exclusion criteria: History/ evidence of other pelvic malignancy 
History of pelvic radiation for other diseases 
Androgen deprivation therapy, T replacement, androgen abuse 
The participants with rectal cancer were enrolled at a tertiary (Karolinska University Hospital) and a secondary 
(Ersta Hospital) referral centre in Stockholm between April 2010 and May 2014. At the Urology depart-ment of the 
Karolinska University Hospital in Stockholm participants with prostate cancer were included between May 2012 
and January 2013. 
All participants had a baseline visit before the start of any oncologic treatment to collect fasting morning venous 
blood samples, semen samples, PROMs and data concerning demographics, medical history and physical examina-
tion. Men under 55 years of age were offered semen cryopreservation. Men treated with preoperative RT for rectal 
cancer had an additional venous blood sample during the week before surgery. Data on surgery, adverse events and 
histopathology were retrieved from clinical records.  
One and two years after surgery the participants had follow-up visits with identical data collection as at baseline and 
testicular stimulation test with human chorionic gonadotropin (HCG), a LH analogue. The study visits took place at 
the outpatient clinic of the Centre for Andrology and Sexual Medicine, Karolinska University Hospital. The partici-
pants could choose if they wanted to participate in hormone analysis, semen sample and/ or PROMs. Semen sam-
pling and cryopreservation was not performed in men with prostate cancer. 
Table 4. Study visits and assessments of the cohort study 
Baseline Prior to surgery* 12 months 24 months 
Androgens Androgens Androgens Androgens 
HCG test HCG test 
PROMs PROMs PROMs 
Semen sample Semen sample Semen sample 
PROM=patient reported outcome measures, HCG=human chorionic gonadotropin 
* men with RT (exposed group), 
Participants were offered to meet an andrologist after every visit to evaluate treatment of sexual dysfunction or 
symptoms of LOH. At any time of the study treatment of erectile dysfunction was possible. The T replacement in 
severe LOH was restricted to the period after the first follow-up visit 12 months postoperatively. 
Approvals and registrations 
We registered the cohort study “Sexual Function and Wellbeing in Males Diagnosed With Rectal Cancer“ at Clini-
calTrials.gov under the identification number NCT01216206. The Regional Ethical Review Board in Stockholm 
approved the study (2009/1860-31/2) and the amendments for inclusion at Ersta Hospital, Södersjukhuset, Dan-
deryd Sjukhus AB, Department of Urology Karolinska University Hospital (2010/1768-32; 2011/2097-32) and for 
analysis of radiologic images performed during cancer treatment (2012/2173-32). The collection of five cone beam 
CT in 30 men treated with short course RT was also approved by amendment (2012/668-32) and by the Radiation 
Protection Authority (K1180-2012 (2012_27)). 
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Radiotherapy and chemotherapy 
The pre-therapeutic MDT conference recommended the treatment modalities according to the guidelines of the 
European Society for Medical Oncology (ESMO) 82. Preoperative RT was given as short course (5 x 5 Gy) or long 
course RT (25 x 2 Gy or 28 x 1.8 Gy). Long course RT with a prescribed dose of 50.4 Gy was combined with con-
comitant chemotherapy (capecitabine). Men with short course RT had usually surgery the following week. Partici-
pants included at the same time to the experimental arm of the “Rectal Cancer And Pre-operative Induction Thera-
py Followed by Dedicated Operation” (RAPIDO) trial had short course RT and six cycles preoperative chemother-
apy (capecitabine and oxaliplatin) 85. 
The oncologists delineated the gross tumour volume (GTV) and the clinical target volume (CTV) on the planning 
CT using the treatment planning system Eclipse (Varian, Palo Alto, CA, USA). The CTV covered, apart from the 
primary tumour and the mesorectum, lymph nodes outside the mesorectum at risk of containing cancer cells 82. The 
pelvic floor was included to the CTV in men planned for extralevator or ischioanal APE. The planning target vol-
ume (PTV) was defined by addition of an isotropic margin around the CTV (6 mm for short course RT and 9 mm 
for long course RT) to account for set up errors. External beam RT was delivered to the undressed patient in supine 
position without specific gonadal protection using a four-field conformal technique with 15 MV or 18 MV photons 
(Varian). Two participants had Volumetric Modulated Arc Therapy (6 MV). 
The expected gains of adjuvant chemotherapy were discussed at the postoperative MDT conference and adminis-
tered on a selective basis. 
Outcome measures 
Venous blood samples 
The blood samples were analysed at the Karolinska University Laboratory. Serum T, LH, FSH, SHBG and Inhibin 
B were measured in the serum. Bioavailable T was calculated under the assumption of constant albumin concentra-
tions (43g/l) according to the method of Vermeulen et. al. 145. The LH-T ratio was calculated by dividing LH with 
serum T. Low serum T was defined as a level of serum T below 8 nmol/l. 
Serum T was measured by chemiluminescent immunoassay using the Access Immunoassay System (Beckman 
Coulter, Inc., Stockholm, Sweden). with a coefficient of variance (CV) < 10% in the range of 6.94 to 34.70 nmol/l. 
Serum LH and FSH were determined with an AutoDELFIA hLH/hFSH assay (PerkinElmer Life and Analytical 
Sciences, Turku, Finland), which is an immunoradiometric assay with CV < 2%. SHBG was assessed by immuno-
assay (Beckman Coulter) with CV 5%. Inhibin B, a marker of spermatogenesis, was measured with the OBI Inhibin 
B ELISA (DSL, Oxford, UK), which has a CV of 7% at 339 ng/l and 15% at 28 ng/l. Chromatography was used to 
determine HbA1c in the blood and the values were reported according to the International Federation of Clinical 
Chemistry in mmol/mol. 
Semen analysis 
We asked men that consented to semen analysis to avoid ejaculation 48h prior to the study visits. Semen samples 
were analysed following the World Health Organisation guidelines from 1999 at the Centre for Andrology and 
Sexual Medicine, Karolinska University Hospital. 
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Patient reported outcome measures 
Sexual function, symptoms of androgen deficiency, quality of life and anxiety/ depression were assessed by ques-
tionnaires that the participants filled in during the study visits to ensure completeness. 
Sexual function International Index of Erectile Function (IIEF)216 
Sexual Complaints Screener for Men (SCS-M) 
Hypogonadism Aging Males’ symptoms rating scale (AMS) 217 
Quality of life European Organization for the Research and Treatment of Cancer (EORTC) Core 
Quality of Life Questionnaire (EORTC QLQ-C30) 218 and colorectal cancer mod-
ule (EORTC QLQ-CR29) 219 
Life Satisfaction checklist (Li-Sat-11) 220 
Anxiety/ Depression Hospital Anxiety Depression Scale (HADS) 221 
Enrolment 
The eligibility for this study was assessed in 372 men with rectal cancer and 115 men were included. The number of 
eligible men with prostate cancer was 298 and 63 men were included to the unexposed group of this study. The 
reasons for non-participation were language/ communication restrictions, residence outside the Stockholm County 
and declined participation. 
!
Figure 10. 
Flow chart
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SPECIFIC METHODS PAPER II TO IV
Paper II 
The expected testicular radiation exposure during preoperative RT for rectal cancer was calculated for 101 
participants with available planning CT. Men treated with short course RT between August 2012 and May 2014 
had repeated cone beam CTs (CBCT) to assess longitudinal differences of TD during the course of RT. The 
CBCTs were acquired in treatment position after each fraction. 
Assessment of planned testicular dose (cross-sectional analysis)
The testicular tissue was delineated on planning CT as one volume excluding other scrotal structures such as skin, 
soft tissue or epididymis to assess the planned TD. The Analytical Anisotropic Algorithm (AAA) of the Eclipse 
system was used to calculate the dose distribution of the testicular volume. The mean TD (mTD), the minimum TD 
and the maximum TD for the complete RT were reported based on the dose-volume histogram as physical doses. 
The shortest distance between the centre of the testicular volume and the lower end of PTV/ beam (distance testes-
PTV) in the sagittal view was also registered. The beam model in Eclipse was not primarily optimized outside the 
geometrical beam. Thus all TDs were adjusted by the factor 1.15 to correct for this systematic underestimation. 
Figure 11. Delineation of target volume and testes (left), respective cumulative dose-volume histogram (right)
Red line=Planning target volume (PTV)
Blue line=Testicular volume 
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Assessment of delivered testicular dose (longitudinal analysis)
The delivered TD for each RT fraction was calculated based on CBCTs with the treatment planning system as de-
scribed above and multiplied by five (number of fractions) to compare the planned and delivered TDs. The image 
quality of CBCT was lower compared to planning CT and the volume of the body scanned with CBCT did not cover 
the complete PTV. To decrease systematic differences of TD calculation between planning CT and CBCT, the size 
of the testicular volume on CBCT was matched with the size on the respective planning CT. The loss of photon 
scattering from the “missing PTV” on CBCT was corrected with individual factors ranging from 1.1 to 1.6. These 
factors were estimated by comparing the effect of an equivalent “missing PTV” on the respective planning CT. The 
observed within-person variability of the delivered TD is due to differences in the position of the testes under the 
assumption of negligible systematic differences of TD calculation between planning CT and CBCT and small set 
up errors. 
Statistical analysis 
The distribution of mTD was skewed and the relationship with the distance testes-PTV was hyperbolic. The distri-
bution of mTD was compared between groups of patients with non-parametric tests (Wilcoxon rank-sum and Krus-
kal-Wallis). We estimated quantile regression models for the 25th, 50th and 75th percentile of the inverse mTD as a 
quadratic function of the distance testes-PTV, exploited the invariance property of the quantiles and estimated the 
quantiles for mTD by inverting the estimates from the above model 222. 
Paper III 
Preoperative RT for rectal cancer determined the exposure status in this cohort study. Men with rectal cancer treat-
ed with preoperative RT were assigned to the exposed group. The unexposed group consisted of men with rectal 
cancer planned to surgery alone or men with prostate cancer planned to robot-assisted prostatectomy. The primary 
endpoint was serum T (continuous variable) and low serum T (categorical variable). Secondary endpoints were 
bioavailable T, LH and the LH-T ratio. All participants had a visit at baseline and men treated with preoperative 
RT had a second blood sample the week prior to surgery. The androgen status relevant at the time of surgery was 
the baseline measurement for the unexposed group and the follow-up measurement for the exposed group. The 
elapsed time between the start of RT and the second blood sample was also registered. 
Quantification of exposure 
The planned TD calculated with the treatment planning system based on planning CT in Paper II was used to quan-
tify the exposure. To account for the additional testicular radiation exposure due to CBCTs, 0.04 Gy was added to 
the individual mean, maximal and minimal TD for every CBCT. The dose-response relationship between TD and 
change in androgen levels was restricted to men treated with short course RT as a different effect for long course 
RT cannot be excluded. 
Statistical analysis 
Groups of patients were compared using t-tests or non-parametric tests as appropriate. Fisher’s exact tests were 
used for count data. A general estimating equation (GEE) approach was chosen to analyse the longitudinal data and 
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to report population-averaged outcomes while allowing for correlation between repeated observations. We com-
pared sexual hormones of all study participants at baseline with sexual hormones in men after preoperative RT for 
rectal cancer prior to surgery to assess the effect of RT on the androgen status at the time of surgery. 
Paper IV 
This was a longitudinal observational study in men exposed to preoperative RT from the described cohort study 
that had planning and one-year follow-up CT available by May 2014. The changes in serum and bioavailable T 
between baseline and the visit 12 months after surgery were the exposure and changes in body composition the 
outcome. Elapsed time denotes the time between the last day of RT and the venous blood sample 12 months after 
surgery. 
Outcome measures 
Data on body composition were retrieved from abdominal CT examinations on a dedicated workstation (Advantage 
Workstation 4.1, GE Medical Systems using AW4.1 Basic Display software). The CT section at the level of the 
inferior surface of the L3 vertebra was selected to delineate manually the area of visceral adipose tissue (VAT), 
subcutaneous adipose tissue (SAT), psoas muscle (PM) 
and erector spinae muscle (EM). The skeletal muscle of 
the abdominal wall was not traced due to potential con-
founding effects of laparotomy and stoma formation 
such as denervation and incisional/ parastomal hernia on 
the longitudinal analysis. The psoas and erector spinae 
muscle were assessed separately and intramuscular adi-
pose tissue (IMAT) was excluded. The average amount 
of disagreement, considering all assessed tissue areas 
(PM, EM and SAT), was 0.4% for the primary investiga-
tor and 0.3% for the second investigator. 
Figure 12. Delineation of skeletal muscle at L3 
Statistical analysis 
Summary statistics were compared between groups of patients using two-sided paired t-tests, Wilcoxon rank-sum, 
Kruskal-Wallis and Fisher’s exact tests. For dependent count data the McNemar’s test was used. The association of 
T levels and body composition during the first year of follow up was analysed with random-effects linear 
regression models. We considered weight, age and LH as potential confounders. Age and LH, however, changed 
the estimated coefficients associated with the exposure variable of interest by less than 10% and were excluded 
from the final models.  
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RESULTS PAPER II TO IV
Paper II 
The testicular dose was analysed in 101 individuals. Seventy-six men were planned to short course RT and 25 men 
were planned to long course RT. The median planned mTD for short course RT was 0.57 Gy (range 0.06 to 14.37 
Gy) and 0.81 Gy (range 0.36 to 10.80 Gy) for long course RT.  
Cross-sectional analysis of planned testicular dose
Increasing distance testes-PTV or distance of the tumour from the anal verge as well as exclusion of the anal canal 
from PTV or surgery with preservation of the pelvic floor (i.e. low anterior resection, intersphincteric APE or 
Hartmann´s procedure) were factors resulting in decreased planned mTD in the stratified analysis. The distance 
between testes-PTV remained a significant predictor in the multivariate quantile regression analysis for the 25th and 
75th percentile of planned mTD. 
Table 5. Stratified analysis of the planned testicular dose 
Short course RT p value Long course RT p value 
Number of men 76 25 
mTD 
minTD 
maxTD 
0.57 (0.06 to 14.37) 
0.33 (0.0 to 7.73) 
1.08 (0.18 to 25.91) 
0.81 (0.36 to 10.80) 
0.48 (0.21 to 1.73) 
1.87 (0.56 to 42.74) 
mTD by distance testes-PTV 
0-1 cm 
1-5 cm 
>5 cm 
4.32 (2.21 to 14.37) 
0.78 (0.33 to 2.35) 
0.27 (0.06 to 0.51) <0.001† 
6.09 (5.40 to 10.80) 
1.31 (0.99 to 2.97) 
0.58 (0.36 to 0.81) <0.001† 
mTD by tumour distance from anal verge 
0-5 cm 
6-10 cm 
11-15 cm 
1.35 (0.18 to 14.37) 
0.50 (0.15 to 14.19) 
0.29 (0.06 to 1.92) <0.001† 
1.16 (0.43 to 10.80) 
0.81 (0.47 to 6.09) 
0.70 (0.36 to 1.67) 0.52† 
mTD by relation of anal canal and PTV 
Anal canal included in PTV 
Anal canal not in PTV 
0.91 (0.15 to 14.37) 
0.34 (0.06 to 0.77) <0.001†† 
1.33 (0.43 to 10.80) 
0.69 (0.36 to 2.59) 0.08†† 
mTD by type of surgery 
Pelvic floor resected 
Pelvic floor preserved 
1.34 (0.18 to 14.37) 
0.37 (0.06 to 4.32) <0.001†† 
1.37 (0.43 to 10.80) 
0.70 (0.36 to 6.09) 0.10†† 
Doses reported in Gy as median (range), RT=preoperative radiotherapy, mTD=mean testicular dose, minTD=minimal testicular dose, maxTD=maximal 
testicular dose, PTV=planning target volume 
† Kruskal-Wallis test, †† Wilcoxon ranksum test 
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Longitudinal analysis of planned and delivered testicular dose
The delivered mTD could be assessed on 127 CBCTs acquired from 32 men treated with short course RT. The 
median planned and averaged delivered mTD was similar (0.52 Gy vs. 0.51 Gy; p=0.84) and the graphical analysis 
showed no systematic difference between 
mTD assessed on planning CT and CBCT. 
The estimated median difference between 
planned and delivered mTD expected for a 
given planned mTD of 1 Gy was smaller 
than 0.5 Gy but this difference increased for 
higher planned mTDs. 
Figure 13. Estimated 25th, 50th, 75th and 90th
percentile of absolute difference between 
planned and delivered mean testicular dose 
for a given planned mean testicular dose. 
TD=testicular dose 
The longitudinal assessment of mTD calculated on planning CT and repeated CBCT can be displayed as spaghetti 
plot. The longitudinal regression analysis confirmed the graphical impression that mTD did not change significantly 
over the time of planning and delivering of short course RT. The differences in the position of the testes during 
planning and delivering of RT, estimated by the distance testes-PTV, had a heterogeneous effect on the within-per-
son variability of mTD. The distance testes-
PTV had no significant effect on within-
person variability of mTD in men with low 
mTD (25th percentile). In men with 
moderate and high mTD (50th and 75th 
percentile) the distance testes-PTV had a 
significant effect on within-person variabil-
ity of mTD. 
Figure 14. Spaghetti plot of planned and 
delivered mean testicular dose for 32 men 
treated with short course RT (25 Gy). 
CBCT=cone beam computed tomography 
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Paper III 
This cohort study consisted of 168 participants, 105 men with rectal cancer and 63 men with prostate cancer. The 
93 men treated with preoperative RT and surgery for rectal cancer were assigned to the exposed group. The number 
of participants in the unexposed group was 75.  Twelve of these men had rectal cancer and were treated with surgery 
alone. The remaining 63 men had robot-assisted prostatectomy for prostate cancer.
In the exposed group 68 men had short course RT and preoperative chemotherapy was given to 34 men. Mean age 
and BMI were higher and the proportion of American Society of Anesthesiologists (ASA) score equal to three was 
lower in the unexposed group. 
Androgen status at baseline 
The levels of serum T, bioavailable T and LH were similar at baseline and no significant differences in the LH-T 
ratio or proportion of low serum T were detected between the exposed and unexposed group. The type of cancer 
and the type of RT were not associated with androgen status at baseline. The regression analysis yielded the same 
finding. 
Table 6. Sexual hormones at baseline according to exposure status 
No RT (unexposed group) RT (exposed group) P value t-test 
Number of participants 75 93 
Serum T (nmol/l) 11.9 ± 4.0 11.3 ± 3.4 0.26 
Bioavailable T (nmol/l) 5.3 ± 1.5 5.0 ± 1.6 0.15 
LH (IU/l) 4.1 ± 2.3 4.5 ± 2.2 0.38 
LH-T ratio (IU/nmol) 0.38 ± 0.31 0.43 ± 0.28 0.25 
Proportion of serum T < 8 nmol/l (%) 15.1 14.3 0.53* 
Hormone measures reported as mean ± standard deviation, RT=preoperative radiotherapy, T=testosterone, LH=luteinising hormone 
* Fisher´s exact test 
Acute effect of preoperative radiotherapy on androgen status
A second blood sample was collected in 79 of 93 men of the exposed group. Preoperative RT resulted in a signifi-
cant decrease of serum T and increase of LH and LH-T ratio independent of the type of RT. The decrease in bioa-
vailable T was significant in men treated with short course RT but not in men with long course RT.  
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Table 7. Difference of sexual hormones in men treated with preoperative radiotherapy for rectal cancer 
Short course RT p value Long course RT p value 
Number of patients 59 20
Mean testicular dose (Gy) 0.65 0.06 to 14.37 
1.02 
0.36 to 10.80 
Elapsed time between start of RT and preoperative 
blood sample (days) 
10 
3 to 195 
96 
57 to 118 
Difference in serum T (nmol/l) - 2.0 ± 3.0 <0.001 -1.3 ± 3.0 0.03 
Difference in bioavailable T (nmol/l) -0.9 ± 1.4 <0.001 -0.5 ± 1.6 0.06 
Difference in LH (IU/l) 0.8 ± 2.0 0.003 2.1 ± 2.2 <0.001 
Difference in LH-T ratio (IU/nmol) 0.27 ± 0.43 <0.001 0.49 ± 0.89 <0.001 
Mean testicular dose and elapsed time reported as median (range), hormone levels as mean ± standard deviation, p values of Wilcoxon signed-rank 
test, RT=preoperative radiotherapy, T=testosterone, LH=luteinising hormone 
The elapsed time between the start of RT and the second blood sample was depended on the type of neoadjuvant 
treatment. A decline of the difference in serum T but an increase of the difference in LH was observed with increas-
ing elapsed time. 
Figure 15. Estimated effect of elapsed time on the difference of serum testosterone and LH in men with rectal can-
cer exposed to preoperative radiotherapy (reference line: difference=0) 
The longitudinal regression analysis confirmed the results above with a significant decrease in serum and bioavaila-
ble T combined with a significant increase in LH and LH-T ratio in men treated with preoperative RT. Age, BMI, 
ASA score, preoperative chemotherapy and elapsed time had no confounding effect on the outcome estimates nor 
could an effect modification of these covariates be detected. 
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Risk of low serum testosterone at the time of surgery
The proportion of all study participants with low serum T at baseline was 14.6 per cent (n=164) and increased to 
35.4% in men treated with preoperative RT for rectal cancer at the time of surgery (n=79). The absolute risk 
increase of 20.8% for low serum T resulted in a number needed to harm (NNH) of 4.8 for preoperative RT of rectal 
cancer. The relative risk of low serum T at the time of surgery was 2.41 (95% CI 1.57 to 3.71, p<0.001) for men 
treated with preoperative RT compared to all study participants at baseline. The regression analysis did not result 
in relevant confounding or effect modulation of age, BMI, ASA score, preopera-tive chemotherapy or elapsed time. 
Dose-response relationship between testicular dose and serum testosterone
The preliminary results of the dose-response analysis restricted to men treated with short course RT resulted in a 
significant interaction between planned mTD and follow-up visit for the models with bioavailable T (p=0.011), LH 
(p<0.001) and LH-T ratio (p=0.004) and a borderline significant interaction for the model with serum T (p=0.055). 
Paper IV 
The longitudinal changes in androgen levels and body composition were analysed in 40 men treated with 
preoperative RT that had completed the study visit 12 months after surgery and the CT for one-year cancer follow-
up was available by May 2014. The average age of these non-obese participants was 60 years and 30 of 40 men had 
short course RT. Almost half of the participants had an extralevator APE and 15 of 40 patients had additional 
tissue/ organs resected. 
Longitudinal change in androgen levels and body composition 
Half of the study population experienced a decrease in serum T resulting in a slight decrease of mean serum and 
bioavailable T and a significant increase in mean LH levels. The frequency of low serum T (< 8 nmol/l) and elevat-
ed LH (> 9 IU/l) increased significantly. 
The mean SAT increased significantly during the first year after surgery for rectal cancer and the mean skeletal 
muscle area did not change. 
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Table 8. Endocrine assessment and body composition data for all study participants (n = 40) at baseline and 12 
months after preoperative radiotherapy and surgery for rectal cancer
Baseline Follow-up P value 
Serum T (nmol/l) 11.5± 3.0 10.9 ± 3.1 0.16* 
Bioavailable T (nmol/l) 5.05 ± 1.7 4.96 ± 1.23 0.09* 
LH (IU/l) 4.3 ± 1.9 6.1 ± 3.1 0.0001* 
Frequency of serum T <8 nmol/l (%) 7.5 15 <0.0001† 
Frequency of LH >9 IU/l (%) 2.5 23 <0.0001† 
SHBG (nmol/l) 43.0 ± 16.8 40.4 ± 12.4 0.41* 
HbA1c (mmol/mol) 38.4 ± 3.8 37.4 ± 4.8 0.09* 
BMI (kg/m²) 24.1 ± 3.2 24.4 ± 3.4 0.43* 
SAT (mm²) 14713 ± 5940 16062 ± 5831 0.004* 
VAT (mm²)‡ 16002 ± 10428 15853 ± 8913 0.86* 
Psoas mucle area (mm²) 2221 ± 568 2292 ± 525 0.06* 
Erector spinae muscle area (mm²) 5145 ± 1211 5048 ± 1121 0.26* 
Values are reported as mean ± standard deviation. T=testosterone, LH=luteinising hormone, SHBG=sex hormone binding globulin, HbA1c=glycated 
haemoglobin, BMI=body mass index, SAT=subcutaneous adipose tissue area, VAT=visceral adipose tissue area 
* t-test, † McNemar’s test, ‡ n=27 
Association between androgen levels and body composition 
The regression analysis adjusted for weight and elapsed time between the last day of RT and the second venous 
blood sample (Model 2) showed no association between the level of serum T and the area of SAT or skeletal 
muscle (PM and EM). The level of bioavailable T was related to the area of the assessed skeletal muscle groups 
(PM and EM) at any time of the study. The area of SAT was not related to bioavailable T. 
Table 9. Regression coefficients of serum and bioavailable testosterone from the random-effects linear regression 
models with area of skeletal muscle and subcutaneous adipose tissue as outcome 
Psoas muscle (mm²) Erector spinae muscle (mm²) SAT (mm²) 
Regression coefficients for serum testosterone as predictor 
Model 1* 2,0 (-21,6 to 25,7) 8,0 (-46,5 to 62,5) -343,6 (-608,8 to -78,4) 
P value 0,866 0,774 0,011 
Model 2† 11,4 (-12,7 to 35,5) 40,2 (-16,6 to 97,0) -140,2 (-358,1 to 77,8) 
P value 0,355 0,166 0,207 
Regression coefficients for bioavailable testosterone as predictor 
Model 1* 49,8 (-1,7 to 101,3) 118,5 (-1,4 to 238,5) -323,5 (-907,9 to 260,9) 
P value 0,058 0,053 0,278 
Model 2† 64,3 (14,4-114,2) 185,9 (67,9-304,0) 8,7 (-442,4 to 459,8) 
P value 0,011 0,002 0,970 
Regression coefficients (95% confidence interval), SAT=subcutaneous adipose tissue area 
* Adjusted for elapsed time, † Adjusted for elapsed time and weight 
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The cross-sectional area of psoas muscle as an androgen-related sign 
At the visit 12 months after surgery 24 of 40 participants had serum T levels in the grey zone of hypogonadism 
(serum T between 8 to 12 nmol/l). The area of psoas muscle increased in 17 and decreased in 7 of 24 potentially 
hypogonad men. The mean LH and mean LH-T ratio were significantly higher in men with loss of psoas muscle. 
Differences in age, BMI, co-morbidity, SHBG and Hba1c were not significant. 
Table 10. Men treated with preoperative radiotherapy for rectal cancer in the grey zone of hypogonadism (serum T 
8-12 mmol/l) 12 months after surgery stratified on the change in psoas mucle area
Increase of psoas 
muscle area (n=17) 
Decrease of psoas 
muscle area (n=7) P value 
Mean ± SD 
Age (years) 60,9 ± 11,6 64,1 ± 11,5 0,45* 
BMI (kg/m²) 25,2 ± 3,6 23,9 ± 4,3 0,39* 
Charlson comorbidity index 0,41 ± 0,51 0,14 ± 0,38 0,21* 
Bioavailable T (nmol/l) 4,3 ± 0,8 4,7 ± 0,6 n.a. 
LH (IU/l) 4,7 ± 2,1 7,7 ± 3,2 0,02* 
LH- T ratio 0,472 ± 0,221 0,743 ± 0,253 0,01* 
SHBG (nmol/l) 42,2 ± 9,2 36,9 ± 9,3 0,19* 
HbA1c (mmol/mol) 37,3 ± 4,4 39,3 ± 5,6 0,40* 
Median (range) 
Tumour distance from anal verge (cm) 5 (1 to 13) 4 (1 to 12) 0,50* 
Count data 
Pathological tumour stage 
Stage I 4 3 0,13‡ 
Stage II 6 4 
Stage III 7 0 
Radiotherapy regimen 
5 x 5 Gy 10 7 0,07‡ 
28 X 1,8 Gy 7 0 
Type of operation 
Low anterior resection 9 3 1,00‡ 
Abdominoperineal excision 8 4 
Postoperative chemotherapy 7 1 0,35‡ 
Adverse events 
Clavien ≥ III 3 2 1,00‡ 
Distant metastasis 2 0 
T=testosterone, SD=standard deviation, BMI=body mass index, LH=luteinising hormone, SHBG=sex hormone binding globulin, HbA1c=glycated 
haemoglobin 
* Wilcoxon rank-sum test, ‡ Fisher’s exact test 
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DISCUSSION AND CONCLUSION 
PAPER II TO IV
Discussion Paper II to IV 
Interpretation Paper II to IV 
The average TD calculated with the treatment planning system was 4.7% of the prescribed dose in 
contemporary RT for rectal cancer, which is low compared to 3% to 17% in the review (Paper I). In a recent 
publication with similar proportion of low rectal cancer and identical method of dose calculation, the TD was 
7.7% of the prescribed dose despite radiation in prone position on double-hole belly board 223. The spatial 
proximity of the testes to the PTV was, as expected by the inverse square law, the strongest predictor of the TD 
and had a hyperbolic relation. This leads to considerable values of TD in men with short distances testes-PTV of 
concern regarding spermatogenesis and Leydig cell function as discussed in the review article 224. The effect of the 
other three investigated predictors of TD (i.e. distance of the tumour from the anal verge, relation of anal canal to 
PTV and type of surgery regarding pelvic floor resection) was weaker. The distance testes-PTV and the distance of 
the tumour from the anal verge can be used to identify men with low TD as men with a distance testes-PTV larger 
than 5 cm or with rectal cancer in the upper third of the rectum (11 to 15 cm from the anal verge) have a 
planned mTD below 2.0 Gy. The relation of the anal canal to PTV and the type of surgery seem not to be 
appropriate to identify individuals with planned mTD below 2.0 Gy.
The longitudinal analysis based on TD calculation by planning CT and repeated CBCT showed that the planned 
TD was similar to the delivered TD. The absolute differences between planned and delivered TD increased 
with increasing planned TD. The observed differences between planned and delivered TD (within-person 
variability) are essentially due to variation in position of the testes during RT. This effect is not important in men 
with low mTD (25th percentile) and the accuracy of the planned TD as an estimate of the delivered TD is within 
0.5 Gy for TDs up to 1 Gy. The variation in position of the testes has a significant impact on within-person 
variability in individuals with median to high TD. This might be a target group with particular profit of gonadal 
protection 200, 225. 
The results of the cohort study (Paper III) indicate that preoperative RT has an acute negative effect on androgen 
levels with a relative risk of 2.4 to have low serum T at the time of surgery. One out of five men treated with pre-
operative RT is expected to drop below the threshold of biochemical hypogonadism (8 nmol/l) and the simultane-
ous increase in LH and LH-T ratio indicate a primary testicular failure. So we can confirm the findings of smaller 
case series regarding the acute effect of RT on Leydig cell function 197 199 202. Studies with a follow-up of two to 
four years report similar values for the risk of biochemical hypogonadism, which indicates that the negative impact 
of RT could be permanent in selected individuals 201 205. The decline in serum T was evident in our study already 
during the first week after RT with a trend of improvement over time. The LH levels increased steadily after RT. 
So it is possible that a proportion of men with serum T above 8 nmol/l in fact have compensated hypogonadism 
characterized by elevated gonadotropins and borderline T. The testicular vulnerability seems not to depend on age, 
BMI, physical status according ASA and preoperative chemotherapy. These risk factors of hypogonadism had no 
impact on the acute adverse effect of RT. The preliminary results of the dose-response analysis indicate that the 
extent of the acute adverse effect of RT on Leydig cell function is related to the TD, which sustains the causal 
relationship. The clinical consequences of the observed preoperative androgen decline on perioperative adverse 
events or oncological outcomes are unknown. Low perioperative T may increase morbidity after abdominal surgery 
and androgens are important for maintenance of skeletal muscle mass and function 158 189.  
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The skeletal muscle mass, assessed by the cross-sectional area of the psoas and erector spinae muscle, is 
androgen-dependent and related to the non-SHBG-bound, bioavailable T. The androgen analysis in this 
subgroup of participants exposed to RT confirms the adverse effect of RT on Leydig cell function. The primary 
testicular failure is evident 12 months after surgery from a significant increase in LH combined with a doubled 
frequency of low serum T. The increment in LH suggests a compensatory attempt to increase T levels and 
indicates a compromised testicular function as described for compensated LOH. The negative effect of RT 
on testicular function persists and implies an elevated long-term risk for development of hypogonadism 
with important consequences on cardiovascular mortality, all-cause mortality and health-related quality of life 
156 157. The cross-sectional area of the psoas and erector spinae muscle, available from routinely performed 
imaging during rectal cancer treatment, can also be used as androgen–dependent sign to assist in clinical 
diagnosis of hypogonadism. This is important in men after pelvic surgery as typical signs of hypogonadism, 
decreased frequency of morning erections and erectile dysfunction, are not reliable due to high frequency of 
impaired erection based on autonomic nerve injury.
Subcutaneous adipose tissue was not related to androgens in our study after adjustment for weight . The amount 
of adipose tissue seems to be related to the joint action of T and oestrogen 148.  The detected minor change of 
mean serum T has a small impact on circulating oestrogen, as oestrogen levels mainly depend on the amount of 
adipose tissue and not on a lack of substrate for conversion to oestrogen. The longitudinal analysis of VAT 
seems not to be reliable in small groups of patients treated for rectal cancer as position of diaphragm and 
bowel content at the moment of CT acquisition affect the area of VAT. The amount of resected/ displaced 
mesocolon and greater omentum during abdominal surgery may also interfere with VAT assessment.
The value of detecting sarcopenia, a risk factor for perioperative adverse events and impaired oncological outcome, 
is debated and seems to be of further interest 177 226 227. It could be of value to investigate sarcopenia and LOH sim-
ultaneously as preoperative RT for rectal cancer can result in primary testicular failure with detectable loss of 
skeletal muscle. 
Validity of the results Paper II to IV 
The subgroup analysed with repeated CBCTs was recruited consecutively without further restrictions beside pre-
scribed dose of 25 Gy. We have reduced measurement bias due to systematic differences between dose calculation 
on planning CT and CBCT. The calculated mean doses may be compared in volumes that have different dose dis-
tributions for each fraction under the assumption of identical radiation sensitivity throughout the testicular volume. 
So the testicular mean dose is a relevant dose measure to relate to clinical effects of testicular irradiation. The risk 
of cremaster reflex induction and undetected dislocation of the dosimeter is absent 198. For these reasons the treat-
ment planning system is preferred over scrotal dosimetry for testicular dose calculation. The effect of different frac-
tionation schemes on testicular function is unknown, so we presented the results separated for short and long course 
RT or adjusted in the regression analysis. The quantile regression respects the skewness of the distribution of TD 
and weight or BMI had no confounding effect as suggested by Budgell et al. 203. The results for long course RT and 
individuals with high TD may be affected by the restricted sample size. 
The assignment to preoperative RT occurred during the pre-therapeutic MDT conference without knowledge 
of androgen or participation status of the patient based mainly on morphologic criteria of rectal cancer disease. 
The baseline androgen levels were similar between the exposed and unexposed group indicating low proba-
bility for selection bias. The clinical importance of statistically significant differences in age, BMI and ASA score 
was small and these factors were not identified as confounders or effect modifiers in later data analysis. The 
rationale to include men with prostate cancer planned to robot-assisted prostatectomy in the unexposed group was 
the following: Both cancer types are adenocarcinoma of the pelvis and can be treated with surgery alone. Robot-
assisted prostatec-tomy is suitable in men with local disease and low risk of nodal involvement, thus not planned 
to RT or androgen deprivation, which are exclusion criteria for the study. The risk of developing prostate cancer is 
not associated with serum levels of androgens and prostatectomy seems not to have an impact on serum T 228, 229.
The androgen levels between men with prostate and rectal cancer were similar in our study. 
The reason for missed blood sample after RT was of logistic nature and not related to androgen levels. The 
increased ASA score in the exposed men missed to follow-up could lead to an underestimation of the association 
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as hypogonadism is related to co-morbidity 153. The risk for misclassification of exposure was absent and the quan-
tification of exposure by calculation of the TD with the treatment planning system based on planning CT results in 
accurate estimates of the delivered TD (Paper II) Misclassification of outcome related to the variation of T level 
within and between the participants must be assumed. But the misclassification of outcome is non-differential lead-
ing to a potential underestimation of the relative risk for low T at the time of surgery. The longitudinal regression 
analysis with GEE produces valid estimates of population-averaged outcomes unrelated to the correlation structure 
of the responses and permitted to use all available observations. The results are unadjusted, as relevant confounding 
or effect modulation by age, BMI, ASA score, SHBG, preoperative chemotherapy or elapsed time was not present. 
The association between androgen levels and specific skeletal muscle groups is explored in a subgroup but the risk 
to find a different physiological interaction between psoas muscle and androgens in an alternative study population 
is small. The observation of psoas muscle increase under T replacement in hypogonad men would strengthen our 
findings of androgen-dependency of the investigated muscle groups. The reproducibility of the tissue area meas-
urements with an amount of disagreement below 0.5% was very high. This precision allows for an assessment of 
the changes in body composition probably superior to common measurements such as lean mass or anthropometric 
measures. The within- and between-person variation of serum T levels could be a reason for the absent association 
in this small group of participants. The analysis is adjusted for the confounding effect of weight but physical activi-
ty was not assessed specifically. The differences in physical ability, assessed by the physical functioning score of 
the EORTC QLQ-C30 questionnaire, seem not to explain the observed changes in area of the assessed skeletal 
muscle groups in this study. 
The internal validity of the studies presented in Paper II and IV may be restricted due to the non-comparative design 
and the small sample size with a certain risk for type II errors. But important conclusions of these publications are 
verified in the comparative study presented in Paper III with robust internal validity. The external validity might be 
restricted by the fact that the frequency of rectal cancer treatment with surgery alone (11%) or anterior resection 
(63%) was rather low. This indicates that the proportion of advanced and low rectal cancer in the study participants 
is higher compared to the general population with rectal cancer, which is not surprising, as the participants were 
enrolled at referral centres. 
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Conclusion Paper II to IV
Paper II 
Testicular dose calculation on planning CT results in an accurate estimation of the delivered TD and the distance 
testes-PTV is the most important predictor of the TD. This permits to identify individuals with low TD if the TD is 
not calculated from the planning CT. The within-person variability of the delivered TD is related to differences in 
the position of the testes in men with moderate to high TD and should be considered during positioning of the pa-
tient. 
Paper III 
The exposure of the testes during RT results in an acute decline of androgen levels due to primary testicular 
failure, which may be dose dependent. One of five men treated with RT is expected to develop low serum T but 
the impact on Leydig cell function implies even a risk of compensated hypogonadism in a larger proportion of 
patients. 
Paper IV 
The negative effect of preoperative RT on testicular function persists 12 months after surgery. The cross-sectional 
areas of the psoas and erector spinae muscle are androgen dependent and can be used as clinical sign of hypogonad-
ism.
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FUTURE PERSPECTIVES
We will verify the results of Paper IV in the whole cohort. The relation between radiation-induced changes of an-
drogen levels and skeletal muscle mass might be of importance for acute and late outcomes of rectal cancer treat-
ment. A simplified method of muscle measurement on cross-sectional images might enhance the clinical applica-
tion of this potentially underestimated information present already today. 
Further follow-up of the cohort study will provide longitudinal data on androgens, sexual function and spermato-
genesis one and two years after surgery for rectal cancer. The late adverse effects of RT on testicular function and 
the consequences on quality of life will be assessed. The dose-response relationship between the testicular dose and 
the outcomes mentioned above will also be further explored. 
These findings will form the basis of a randomized trial testing the hypothesis whether early intervention can reduce 
the impact of rectal cancer treatment on sexual function. PDE5-inhibitors and testosterone are interesting substances 
in the context of penile rehabilitation and treatment of testicular failure. Their effects on erectile function in men 
treated for rectal cancer are not well studied and may even have an impact on penile fibrosis, sexual desire or body 
composition. 
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